Drug, bio-affecting and body treating compositions inventions 10/07

20070249519 - Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease: The present invention is directed to novel compositions and their application as pharmaceuticals for the treatment of disease. Methods of upregulation of GLUT4 via activation of peroxisome proliferator activated receptor delta activity in the adipose tissue of a human or animal subject are also provided, for the treatment of conditions... Agent: Global Patent Group Attn: Ms Lavern Hall

20070249536 - Three-component polyanhydride copolymers and a method of forming the same: A three-component polyanhydride copolymer having tunable erosion properties includes a sebacic acid anhydride precursor, a 1,3-bis(carboxyphenoxy) propane anhydride precursor, and a poly(ethylene glycol) anhydride precursor. The erosion rate of the copolymer increases with an increasing amount of the poly(ethylene glycol) precursor. A method for forming the three-component polyanhydride copolymer includes... Agent: Julia Church Dierker Dierker & Associates, P.C.

20070249543 - Dissolution of arterial cholesterol plaques by phytochemical emulsifiers: As a result of this phyto-pharmacological direct action upon the atherosclerotic plaque by the phytocompound resulting in the dissolution of the cholesterol aggregates of the plaque, the plaque is no longer vulnerable to rupture and arterial flow is restituted to physiological values present prior to plaque formation. This effect on... Agent: Filiberto Zadini

20070249556 - Method of treating inflammation: This invention provides methods of preventing and/or treating diseases or conditions associated with inflammation in a mammal, particularly a human. The method comprises administering to a mammal in need thereof an effective amount of a compound of Formula I, IA, or IB, wherein said amount is effective to inhibit inflammation.... Agent: Howery LLP

20070249561 - pharmacological method for treatment of neuropathic pain: Disclosed are methods and compositions useful for treatment of neuropathic pain. In particular, the present invention provides methods of activating gamma-subtype peroxisome proliferator-activated receptors (PPARγ) to inhibit, relieve, or treat neuropathic pain.... Agent: Adams And Reese LLP

20070249518 - Compositions and methods for treating mental disorders: The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia or bipolar disorder. The present invention more particularly discloses the identification of human genes that can be used for the diagnosis, prevention and treatment of schizophrenia, bipolar disorder and related disorders, as... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070249522 - Injectable formulations containing succinate: The invention is directed to formulations of a pharmaceutically active agent for in vivo use. The formulations to which the invention is directed are designed to minimize the pain associated with components in injectable formulations, other than the pharmaceutically active agent. The invention is particularly directed to buffers that provide... Agent: Novartis Vaccines And Diagnostics Inc.

20070249520 - Stable emulsion formulations: The present invention relates to injectable formulations of irritant agents, such as calcimimetics, that are pharmaceutically stable and demonstrate a reduced incidence of irritation, pain, phlebitis, precipitation and hemolysis upon injection.... Agent: Marshall, Gerstein & Borun LLP

20070249521 - Synthetic antimicrobial polypeptides: The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.... Agent: Novozymes North America, Inc.

20070249524 - High affinity ligands bind to clostridium difficile toxin a: Glycans are identified which have high affinity for C. difficile toxin A. They share one of two saccharide backbones and may have additional side chains. The backbones are galactose-β1-3 N-acetyl-D-glucosamine-β-1-3-galactose-β-1-4-N-acetyl-D-glucosamine and galactose-α-1-3-galactose-β-1-4-N-acetyl-D-glucosamine. The ligands may be used therapeutically, prophylactically, and diagnostically.... Agent: Banner & Witcoff, Ltd.

20070249523 - Neurotherapeutic composition and method therefor: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are β-lactam compounds, particularly penam and cephem β-lactam antibiotics and non-antibiotic derivatives thereof.... Agent: Barnes & Thornburg LLP

20070249525 - Use of erythropoietin in the treatment of rheumatoid arthritis: A novel use of the known protein erythropoietin (EPO), and/or a derivative, and/or a fragment thereof, is disclosed. EPO is used as a pharmaceutical for the treatment of chronic inflammations. A particularly beneficial result is seen in patients suffering from rheumatoid arthritis (RA). Significant effects are seen in clinical variables... Agent: Trask Britt

20070249527 - Cyclosporin derivatives for the treatment of immune disorders: where Q, W, X, Y, and Z are defined herein. In a second embodiment, the present invention relates to pharmaceutical compositions comprising pro-drugs or pharmaceutically acceptable salts of the compounds of the present invention and the use thereof for treating autoimmune diseases or for the prevention of organ transplantation rejection... Agent: Elmore Patent Law Group, PC

20070249526 - Process for the preparation of cyclic peptides: The present invention relates to a process for the preparation of cyclic peptides, in particular the preparation of Ac-Phe[Orn-Pro-D-Cha-Trp-Arg] known as 3D53 or PMX53 which is a macrocyclic peptidomimetic of the human plasma protein C5a and displays excellent anti-inflammatory activity.... Agent: Haynes And Boone, LLP

20070249538 - soluble tnf receptors and their use in treatment of disease: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular,... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070249537 - Absorption enhancing agents: Disclosed are new compounds that increase the absorption of pharmaceutical agents across mucous membranes. These absorption enhancers allow higher bioavailability of administered drugs. The enhancers advantageously have low or no cytotoxicity.... Agent: Foley And Lardner LLP Suite 500

20070249530 - Bcma polypeptides and uses thereof: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention... Agent: Merchant & Gould PC

20070249529 - Compositions comprising polypeptides: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding... Agent: Fulbright & Jaworski L.L.P.

20070249528 - Histamine binding compounds for treatment method for disease conditions mediated by neutrophils: The invention relates to a novel method for the treatment of disease conditions that are mediated by neutrophil cells. The method involves the administration to a patient suffering from such a condition, a histamine binding compound in a therapeutically-effective amount.... Agent: Klauber & Jackson

20070249533 - Il-17a and il-17f antagonists and methods of using the same: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are... Agent: Zymogenetics, Inc. Intellectual Property Department

20070249531 - Method for the detection of autoantibodies against specific peptides and its use in diagnosis and treatment of pregnancy-loss or infertility: A method of assessing the titre of fertility-relevant autoantibodies of a mammalian female, wherein said method comprises: the presentation of a defined single molecule capable of binding to the idiotype of the fertility-relevant autoantibody, and determining the amount of autoantibody being bound by said molecule from a sample of a... Agent: Venable LLP

20070249535 - Methods for treating bone tumors: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070249532 - Modified growth hormones: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... Agent: Fish & Richardson, PC

20070249534 - Novel medicament for treating neurodegenerative diseases: A medicament for treating neurodegenerative diseases, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from the C-terminal of selenoprotein P. An excellent medicament for treating neurodegenerative diseases, especially suitable for treating neurodegenerative diseases with ataxia as a principal symptom is... Agent: Birch Stewart Kolasch & Birch

20070249539 - Use of vegf and homologues to treat neuron disorders: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion... Agent: Amster, Rothstein & Ebenstein LLP

20070249540 - Methods for inhibiting proteasome and heat shock protein 90: The present application provides methods for the inhibition of proteasome and heat shock protein Hsp90.... Agent: Adonia Papathanassiu

20070249541 - Combined use of enzyme inhibitors and of pharmaceutical compositions thereof: Provided are combinations of inhibitors of dipeptidyl peptidase IV (DP IV) and of enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) and use of the same to obtain a... Agent: Hodgson Russ LLP The Guaranty Building

20070249542 - Treatment and prophylaxis of sepsis and septic shock: A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.... Agent: Powell Goldstein LLP

20070249544 - Crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249545 - Dihydrofolate reductase inhibition by epigallocatechin gallate compounds: This invention relates to the identification, production and use of Dihydrofolate Reductase (DHFR) inhibitors based on the green tea catechin Epigallocatechin Gallate (EGCG). These inhibitors are, for example, useful in therapy, in particular for the treatment of cancer, infection and inflammatory conditions.... Agent: Klarquist Sparkman, LLP

20070249546 - Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them: The invention relates generally to concentrates and aqueous solutions for topical application comprising antifungal additives or agents as well as to preparation and use of such concentrates and solutions. More specifically, the invention relates to preparation and use of solutions that come in contact with the eye lids and/or eyes,... Agent: Darby & Darby P.C.

20070249547 - Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and... Agent: Connolly Bove Lodge & Hutz LLP

20070249548 - Nucleoside analog or salts of the same: It is an object to provide a nucleoside analog that can produce an oligonucleotide analog in which the two properties of chemical and biological stability, and the ability to form double strands, are excellent, and an oligonucleotide analog that includes that nucleoside analog. This is achieved by a nucleoside analog... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070249551 - Compositions and methods for non-parenteral delivery of oligonucleotides: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070249552 - Compositions and methods for sirna inhibition of primate polyomavirus genes: RNA interference using small interfering RNAs which are specific for mRNA produced from the JCV agnoprotein and large T antigen genes inhibits expression of these and other primate polyomavirus genes. Primate polyomavirus infection, and diseases which are associated with primate polyomavirus infection, can be treated by administering the small interfering... Agent: Nath & Associates

20070249549 - Compounds and methods for rna interference of the p65 subunit of nf-kappa-b: This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA). Furthermore the invention provides methods for preventing, treating or... Agent: Morrison & Foerster LLP

20070249554 - Methods for therapy of neurodegenerative disease of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified... Agent: Stacy L. Taylor, Esq. Dla Piper US LLP

20070249550 - Modulation of immune response and inflammation by targeting hypoxia inducible factors: Methods for modulating inflammation by administering HIF-1α inhibitors or compounds affecting HIF-1α expression and/or transcriptional activities are disclosed. HIF-1α affecting compounds include compounds that directly inhibit HIF-1α and/or interfere into expression of other proteins and regulation of biochemical pathways that target HIF-1α for degradation in vivo. Also disclosed are methods... Agent: Elmore Patent Law Group, PC

20070249553 - Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter: Nucleic acids encoding Campylobacter proteins, in particular antigenic proteins such as a flagellin, or encoding a variant thereof, or a fragment of either of these, are capable of protecting poultry such as chickens, against colonisation by Campylobacter, and so may be used in veterinary therapy or prophylaxis. This has an... Agent: The Mccallum Law Firm, P. C.

20070249555 - Use of atp analogues for treatment of cardiovascular diseases: Use of N-alkyl-2-substituted ATP analogues, pharmaceutically acceptable salts, metabolites or prodrugs thereof, for the preparation of a medicament intended to be used in the prevention and/or the treatment of cardiovascular diseases, pharmaceutical compositions comprising such compounds and a method for screening such compounds.... Agent: Oliff & Berridge, PLC

20070249557 - Compositions and methods for viscosupplementation: The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and a tribonectin, or an analog, derivative, or fragment thereof. Such compositions are useful for the lubrication and chondroprotection of mammalian joints.... Agent: Clark & Elbing LLP

20070249558 - System and method for promoting coronary angiogenesis: Systems and methods for promoting coronary angiogenesis employ a combination of mechanical, metabolic and biochemical stimuli.... Agent: Medtronic, Inc.

20070249559 - Hydrating composition: The present invention relates to methods and compositions for enhancing the ability of the body to absorb ingested water and retain water in the tissues. Compositions and methods of the invention may be used for increasing athletic performance in the heat, as well as for preventing and treating dehydration. The... Agent: Dann, Dorfman, Herrell & Skillman

20070249560 - Hydrolysis resistant organomodified silyated surfactants: Organomodified silylated surfactant compositions that exhibit resistance to hydrolysis over a wide pH range... Agent: Momentive Performance Materials Inc.IPLegal

20070249562 - Treatment of atrial fibrillation: The invention includes a method of treating atrial fibrillation in a mammal that includes administering a therapeutically effective amount of at least one therapeutic compound Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxic acid, pyridoxamine, pyridoxal, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof,... Agent: Merchant & Gould PC

20070249563 - Process for preparing fosphenytoin: Processes for preparing fosphenytoin.... Agent: Dr. Reddy's Laboratories, Inc.

20070249564 - Novel phosphorus-containing prodrugs: o

20070249565 - Class of gamma delta t cells activators and use thereof:

20070249566 - Compositions and methods useful for treatment of respiratory illness: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070249568 - 17,20(e)-dehydro vitamin d analogs and their uses: This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25 -dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249567 - 2-methylene-19,26,27-trinor-(20s)-1alpha-hydroxyvitamin d3 and its uses: This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249569 - 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses: This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20070249570 - Homogeneously formulating microdosed active principles: A microdose of at least one active principle is essentially homogeneously formulated within at least one excipient therefor, via the following steps: 1. weighing the at least one active principle in a receptacle lined with a petroleum jelly; 2. encapsulating the active principle with additional petroleum jelly; 3. introducing the... Agent: Buchanan, Ingersoll & Rooney PC

20070249571 - Novel conjugate compounds and dermatological compositions thereof: The invention relates to novel cosmetic and dermatological compositions, comprising conjugate compounds, including a dicarboxylic acid moiety, which is covalently linked through covalent bonds to a biologically active alcohol, selected from the group of steroidal hormones, steroidal anti-inflammatory agents, vitamin E and vitamin D.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070249573 - 17alpha-substituted 4-(3-oxoestra-4,9-dien-11beta-yl)-benzoic acid, its derivatives and process for its production: This invention relates to 17α-substituted 4-(3-oxoestra-4,9-dien-11β-yl)-benzoic acids and derivatives thereof, a process for the production of these compounds, the use of the compounds for the production of pharmaceutical agents as well as pharmaceutical compositions that contain these compounds.... Agent: Millen, White, Zelano & Branigan, P.C.

20070249572 - Systems and methods for the delivery of corticosteroids: The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic... Agent: Wilson Sonsini Goodrich & Rosati

20070249574 - Stanol composition and the use thereof: A stanol composition containing in addition to sitostanol as the main component, also a substantial amount of at least 10% campestanol has been found to effectively lower serum cholesterol levels when incorporated in edible commodities. Upon esterification the composition is especially useful in edible fats and oils and in fat-containing... Agent: Arent Fox PLLC

20070249575 - Vascular endothelial receptor specific inhibitors: The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.... Agent: Feldmangale, P.A.

20070249576 - Cefdinir oral suspension: The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.... Agent: Steven F. Weinstock Abbott Laboratories

20070249577 - Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070249578 - New amidino derivatives and their use as thrombin inhibitors: e

20070249579 - Diketo-piperazine and piperidine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249580 - Novel cyclic amino benzoic acid derivative: [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or —(CH2)n— (n represents 0, 1 or 2); X represents a hydrogen atom, halogen atom, lower... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249581 - Abnormal cannabidiols as agents for lowering intraocular pressure: h

20070249583 - Hmg-coa reductase inhibitors:

20070249582 - Method of treating substance abuse with quetiapine: This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249584 - Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof: The invention relates to the preparation of substituted caprolactams, a method for the preparation thereof, compositions containing them and the use thereof as a medicament, particularly as anticancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249585 - Triazolobenzodiazepines and their use as vasopressin antagonists: R1 and R2 independently represent C1-6 alkyl; and Ring A represents a phenyl ring or a pyridinyl ring; may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including... Agent: Pfizer Inc

20070249586 - Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity:

20070249587 - Aromatic-ring-fused pyrimidine derivative: There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249589 - Novel diazepan derivatives: wherein A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070249588 - Nicotinic acetylcholine receptor ligands: Acetylcholine receptor ligands of formula (I), wherein D, Ar1, E and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249590 - Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders: e

20070249591 - Biaryl amino acids and their use in dna binding oligomers: Compounds of formula (1): Z′-CO-A-B—NH-Z (I) wherein: Z is H or an amino protecting group; Z′ is OH, a protected or activated hydroxyl group or Cl; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.... Agent: Michael Best & Friedrich LLP

20070249592 - Use of selected cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients: The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, and to the use of said active compounds... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249593 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249594 - Benzothiazine and benzothiadiazine compounds: e

20070249595 - Novel enantiomeric pure beta agonists, manufacturing and use as a medicament thereof:

20070249596 - Abnormal cannabidiols as agents for lowering intraocular pressure:

20070249597 - Pyrazoloquinolones are potent parp inhibitors:

20070249598 - Derivatives of 8-substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Heller Ehrman LLP

20070249600 - Chemical compounds: Benzimidazole derivatives, which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249599 - Novel chemical compounds: This invention relates to the newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249601 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249603 - 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders: s

20070249604 - 3-monosubstituted tropane derivatives as nociceptin receptor ligands: R7 is H or alkyl; and m and n are each 0-6, provided that the sum of m and n is 0-6; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions thereof, and the use of said compounds in the treatment of cough, pain, anxiety, asthma, depression, alcohol abuse,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070249602 - Abnormal cannabidiols as agents for lowering intraocular pressure:

20070249605 - Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof: This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070249606 - Morpholinyl piperidine glycine transporter inhibitors: The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.... Agent: Merck And Co., Inc

20070249607 - Nk-1 and serotonin transporter inhibitors: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249608 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249609 - Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses: e

20070249610 - Process for the preparation of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester:

20070249611 - Dipeptidyl peptidase inhibitors:

20070249614 - Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof:

20070249615 - Pyridine [3,4-b] pyrazinones:

20070249613 - Reduction of toxicity of multi-targeting antifolates: The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting anti-folate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action... Agent: Harness, Dickey & Pierce, P.L.C

20070249616 - Substituted 1-benzyl-4-substituted piperazine analogues: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are... Agent: Cantor Colburn, LLP

20070249612 - Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors: The invention relates to compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.... Agent: Pfizer Inc.

20070249617 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists: e

20070249618 - Novel piperidine derivatives as histamine h3 receptor ligands for treatment of depression: Compounds of formula (I) wherein Ar1 and Q are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of depression.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249619 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof: Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070249622 - Nicotinic receptor agonists and analogues and derivatives thereof for the treatment of inflammatory diseases: This invention relates to the use of nicotine receptor agonists or analogues or derivatives thereof for treating inflammatory pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary... Agent: Buchanan, Ingersoll & Rooney PC

20070249621 - Pharmacological treatment of parkinson's disease: The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.... Agent: Medlen & Carroll, LLP

20070249620 - Urea derivative: [wherein R1 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070249623 - 1-(indole-6-carbonyl-d-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine d-tartrate: 1-(Indole-6-carbonyl-D-phenylglycinyl)-4-(1-methyl-piperidin-4-yl)piperazine D-tartrate forms a stable crystalline salt and is an inhibitor of the serine protease, Factor Xa, useful in the treatment of cardiovascular disorders.... Agent: Eli Lilly & Company

20070249624 - 4-squarylpiperazine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with 4-squarylpiperazine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070249625 - Il-8 receptor antagonists: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249626 - Diaza heterocyclic amide compounds and their uses: i

20070249627 - Tubulin inhibitor and process for its preparation: The invention provides 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which is a tubulin inhibitor useful in the treatment of cancer and processes of making said hemifumarate.... Agent: Wyeth Patent Law Group

20070249630 - Phenethanolamine derivatives for treatment of respiratory diseases: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249628 - Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons: The present invention relates to a method for treating patients exposed to chemical or biological weapons comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more... Agent: Foley And Lardner LLP Suite 500

20070249629 - Viral polymerase inhibitors: e

20070249631 - Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds:

20070249632 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249633 - 1,2,4-triazolo[1,5a] pyrimidines and use thereof for controlling plant-pathogenic fungi: R3 and R4, R6 and R7, R8 and R9 and/or R10 and R11 together with the nitrogen atom to which they are attached form a four-, five- or six-membered saturated or partially unsaturated ring which may be substituted as defined in the description; and n is 0 or an integer... Agent: Birch Stewart Kolasch & Birch

20070249634 - Triazolopyrimidine compounds and use thereof for controlling harmful fungi: R3, R4, R5, R6, R7, R8, R9, R10 and R11 are independently of one another selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl and alkynyl, where the 4 last-mentioned radicals may be substituted as defined in the description; or R3 and R4, or R6 and R7, or R8... Agent: Birch Stewart Kolasch & Birch

20070249635 - Fungicidal mixtures based on a triazolopyrimidine derivative and a conazole: ,

20070249637 - Inhibitors of hepatitis c virus protease, and compositions and treatments using the same: The present invention provides compounds of formula (I), (II) or (IV), or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of the Hepatitis C virus (HCV) protease enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals, including humans. The present invention also... Agent: Pfizer Inc

20070249636 - Selected fused heterocyclics and uses thereof: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20070249638 - Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments: R1 is C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl; R2 is hydrogen, C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl, C6-C14 aryl or C6-C14 aryl(C1-C6) linear or branched alkyl or C6-C14 aryl(C1-C6) linear or branched alkenyl, with the aryl group optionally substituted by... Agent: Nixon & Vanderhye, PC

20070249639 - Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives: The invention relates to the use of 9H-purine-2,6-diamine compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 9H-purine-2,6-diamine compounds, novel 9H-purine-2,6-diamine compounds, and a process for the preparation of the novel 9H-purine-2,6-diamine compounds.... Agent: Novartis Corporate Intellectual Property

20070249640 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070249641 - Adenosine a3 receptor modulators: wherein R, R2, R3 and A have the meanings given in the specification, are endowed with selective A3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A3 receptor, or can be used in a diagnostic application... Agent: Christopher A Klein King Pharmaceuticals, Inc

20070249642 - Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione: e

20070249643 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Robert Deberardine Abbott Laboratories

20070249644 - Compounds and methods for the treatment of asthma: Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS. An example is:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070249645 - Thiazole compounds useful as inhibitors of protein kinase: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein... Agent: Vertex Pharmaceuticals Inc.

20070249647 - Substituted cis- and trans-stilbenes as therapeutic agents: The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a... Agent: Coleman Sudol Sapone, P.C.

20070249646 - Use of tetrahydropyridines in the treatment of central nervous system disorders: Disclosed are methods for alleviating symptoms of neuropsychiatric disorders using tetrahydropyridine derivatives bearing aromatic substituents. The method comprises administering to an individual a tetrahydropyridine derivative bearing aromatic substituents in an amount effective to alleviate symptoms of the neuropsychiatric disorder.... Agent: Hodgson Russ LLP The Guaranty Building

20070249649 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249648 - Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases: The invention provides compounds of general formula. wherein A, B, W, X, Y, Z, D, E, R1 and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20070249651 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and -α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an antineoplastic topoisomerase I or II inhibitor, in the treatment of tumors. Also provided is the use of the said combinations in... Agent: Nikaido, Marmelstein, Murray & Oram LLP Metropolitan Square

20070249650 - Methods for preparing dehydrocavidine, dehydroapocavidine or their composition, their use and medicinal compositon containing them: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then... Agent: Ruay L. Ho Ipfortune LLC

20070249652 - Phenanthridinium derivatives as dna binding agents: New classes of heterocyclic aromatic cationic compounds are disclosed, and in particular new classes of phenanthridinium derivatives, most notably dihydro-imidazo-phenanthridinium (DIP) compounds. These findings are based on the reaction of the middle b ring of a phenanthridinium core with primary amines to form DIP compounds (Formula A) or secondary amines... Agent: Dann, Dorfman, Herrell & Skillman

20070249653 - Tetracyclic benzamide derivatives and methods of use thereof: The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070249654 - Method for controlled polymerization of o-carboxy anhydrides derived from alpha-hydroxy acids: The invention concerns a method for preparing poly(-hydroxy acids), the polymerization reaction being performed in controlled manner in the presence of a catalytic system including a base, said base being a 5- or 6-membered aromatic heterocycle comprising at least one endocyclic nitrogen atom, provided that when the base is used... Agent: Foley And Lardner LLP Suite 500

20070249655 - 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones: the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(═O), C(═O)OH, C1-4alkyloxyC(═O), C1-4alkylC(═O), mono- or di(C1-4alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N-(C1-4alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-4alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl,... Agent: Philip S. Johnson Johnson & Johnson

20070249656 - Hfa suspension formulations containing an anticholinergic: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl -3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070249657 - 1-aza-bicyclo3.3.1nonanes: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein... Agent: Novartis Corporate Intellectual Property

20070249659 - Imidazopyridine compound: wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic... Agent: Merck And Co., Inc

20070249658 - Pyrrolo[3,2-c]pyridine deriatives and processes for the preparation thereof: The present invention provides novel pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20070249660 - Pharmacologically acceptable salts of clopidogrel: The invention relates to polymorphous forms of (+)-(S)-clopidogrel hydrogen bromide, described as polymorphous “form A”, polymorphous “form B”, polymorphous “form C”, polymorphous “form D”, polymorphous “form E”, and polymorphous “form F”, in addition to polymorphous forms of (+)-(S)-clopidogrel napsylate, that are described as polymorphous “form A” and polymorphous “form B”... Agent: Hoffmann & Baron, LLP

20070249662 - Process for the preparation of pyridine compounds: e

20070249661 - Compounds for inflammation and immune-related uses:

20070249663 - Pyrazolo[1,5-a]pyridines and medicines containing the same: [wherein R1 represents methoxy, ethyl, methylthio, etc., R2, R3 and R4 each represent hydrogen, a halogen, etc., R5 and R6 each represent —X5—X6—X7 (wherein X5 represents a single bond or —CO—, X6 represents a single bond, —NR3a, etc. and X7 and R3a each represent hydrogen, C1-10 alkyl, etc.), and Ar... Agent: Birch Stewart Kolasch & Birch

20070249664 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070249665 - 1-aryl-4-substituted isoquinolines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to... Agent: Edwards Angell Palmer & Dodge LLP

20070249666 - P2x7 antagonists to treat affective disorders: The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X7 receptor and pharmaceutical compositions thereof, or combinations.... Agent: Robert Deberardine Abbott Laboratories

20070249667 - Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases: the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the above compounds and one or more other... Agent: Philip S. Johnson Johnson & Johnson

20070249668 - Control of atp release by red blood cells and therapeutic applications thereof: The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCs treated with insulin accumulate significantly less cAMP and release significantly less... Agent: Saint Louis University Office Of Innovation And Intellectual Property

20070249669 - Crystalline 2-amino-3-cyanoquinoline derivatives, process of their preparation and pharmaceutical compositions containing them: The invention relates to the crystalline and amorphous forms of the desmotrope of general formula IB and its salts and solvates, and their preparation.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249670 - Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof: The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249671 - Pharmaceutical composition for piperidinoalkanol compounds: The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249674 - Crystalline forms of a dimethylphenyl compound: The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example,... Agent: Theravance, Inc.

20070249675 - Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary... Agent: Theravance, Inc.

20070249672 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070249673 - Method for administering tolperisone: The present invention is directed to methods of administering tolperisone (2,4′-dimethyl-3-piperidinopropiophenone; 1-propanone, 2-methyl-1-(4-methylphenyl)-3-(-piperidinyl)), and kits comprising the same.... Agent: Robins & Pasternak LLP

20070249676 - Cyanoguanidine prodrugs: e

20070249677 - Treatment of osteoarthritis and dosing regimen for arzoxifene: The present invention provides a method for treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof.... Agent: Eli Lilly & Company

20070249680 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249679 - Imidazol-2-one compounds useful in the treatment of various disorders: e

20070249678 - Synthesis and uses of pyroglutamic acid derivatives: Novel pyroglutamic acid derivatives (I), wherein R1 is −OH, −ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing... Agent: Moore & Van Allen PLLC

20070249681 - Bupivacaines: The present invention describes a new method for the separation of bupivacaine enantiomers consisting in a continuous separation process performed without heating, by the selective precipitation of their diastereomeric salts with tartaric acid. This heatless process avoids the degradation of the reagents granting a continuous process feature to the procedure.... Agent: Birch Stewart Kolasch & Birch

20070249683 - Dicarboxamide derivatives: e

20070249682 - Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications: The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070249684 - Solid forms of the magnesium salt of s-omeprazole and processes for their preparation: New solid forms of the active ingredient magnesium salt of S-omeprazole, obtainable by a preparation process including: a) crystallizing a magnesium salt of S-omeprazole from a solution of a magnesium salt of S-omeprazole in a solvent system that includes a mixture of methanol/water with an amount of water equal to... Agent: Berenbaum, Weinshienk & Eason, P.c

20070249685 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent: Philip S. Johnson Johnson & Johnson

20070249686 - Modulators of crth-2 receptor activity for the treatment of prostaglandin d2 mediated diseases: The invention relates to substituted acids as useful pharmaceutical compounds for treating respiratory disorders as asthma, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20070249687 - Carbamoylpyridone derivatives having inhibitory activity against hiv integrase: R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted amino, optionally substituted lower alkylamino, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclic group, or optionally substituted heterocyclic lower alkyl) or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249688 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using... Agent: Eli Lilly & Company

20070249689 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Pdl Biopharma, Inc. Attn: Legal Department

20070249690 - N-[2-(4-pyridinyl)ethyl]benzamide derivatives as fungicides: o

20070249691 - Mercaptoimidazoles as ccr2 receptor antagonists: a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine, a polymorphic form or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C1-4alkyl)amino, nitro, aryl or aryloxy;... Agent: Philip S. Johnson Johnson & Johnson

20070249692 - Inhibitors of crystallization in a solid dispersion: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may... Agent: Steven F. Weinstock Abbott Laboratories

20070249693 - Total synthesis of salinosporamide a and analogs thereof: The present invention relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein... Agent: Knobbe Martens Olson & Bear LLP

20070249694 - Metaxalone formulations and methods for the preparation thereof: The invention provides pharmaceutical metaxalone compositions having improved bioavailability, food effect, and/or relative food effect, as well as methods of making such metaxalone compositions.... Agent: Kenyon & Kenyon LLP

20070249695 - Preventive and/or therapeutic agents for meniere's disease: The present invention relates to preventive and/or therapeutic agents for Meniere's disease, which comprise a leukotriene antagonist (such as pranlukast hydrate) as an active ingredient. Leukotriene antagonists (such as pranlukast hydrate) are effective in ameliorating various symptoms, such as hearing impairment, tinnitus, a feeling of fullness in the ear and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070249696 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070249698 - Cck-1 receptor modulators: Certain imidazole compounds are CCK1 modulators useful in the treatment of CCK1 mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20070249697 - Novel imidazolidine derivatives: A is cyano or the like; B is hydrogen, halogen, or the like; X1 and X2 are each independently selected from O and S; E is a C1-4 alkyl group; and R1, R2, R3 and R4 are each independently selected from a hydrogen atom and a C1-C6 alkyl group, and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070249699 - Pesticide compositions and methods for their use: This invention relates to agricultural compositions, particularly pesticidal compositions which find particular use as a fungicide or herbicide composition. The pesticidal composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070249700 - Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke: i

20070249701 - Cyclic amine ccr5 receptor antagonists: Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, as an active ingredient.... Agent: Sughrue Mion, PLLC

20070249702 - Calcilytic compounds: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.... Agent: Nps Pharmaceuticals, Inc.

20070249703 - (hydroxyphenyl)-1h-indole-3-carbaldehyde oxime derivatives as estrogenic agents: e

20070249704 - Process for the preparation of fluvastatin sodium salt: The present invention is directed to a process for preparing Fluvastatin Sodium salt by basic hydrolysis of its alkyl ester. The reaction is performed in conditions suitable to allow a selective hydrolysis of the desired syn isomer, while the unwanted anti isomer is removed by extraction, thus reducing its content... Agent: Dickstein Shapiro LLP

20070249705 - N-(1-(2,3-dihydro-1h-inden-5yl)-2-oxo-3-pyrrolidinyl)-sulfonamide derivatives for use as factor xa inhibitors: and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070249706 - Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms): d

20070249708 - C7 ester and c10 hydroxy substituted taxanes: Taxanes having an ester substituent at C(7), a hydroxy substituent at C(10), and a range of C(2), C(9), C(14), and side chain substituents.... Agent: Senniger Powers

20070249707 - Taxanes having c7 hydroxy and c10 heterosubstituted acetate substituents: Taxanes having a heterosubstituted acetate substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substituents.... Agent: Senniger Powers

20070249709 - Crystal forms of (s)-(8(2,6-dichlorophenyl)-6-fluoro-2,3-dihydro benzo[b][1,4]dioxin-2-yl)methanamine hydrochloride salt: The present invention is directed to crystal forms of the 5-HT2C agonist (S)-(8-(2,6-dichlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine hydrochloride, as well as compositions, processes of preparation, and uses thereof.... Agent: Fish & Richardson P.C.

20070249710 - Biaromatic compounds and cosmetic/pharmaceutical applications thereof: e

20070249712 - Peracetic teat dip: A teat dip formula is disclosed for use on dairy animals with the objective of reducing or preventing mastitis. The teat dip formula preferably includes up to about 2% of peracetic acid in solution made by mixing acetic acid, hydrogen peroxide, and from up to about 5% by weight of... Agent: Smith Law Office

20070249711 - Triterpene compounds which are effective on improvement of brain function: The present invention relates to the triterpene compounds improving in brain functions. In particular, the present invention relates to a novel use of the triterpene compounds represented by the Formula 1 for improving decreased memory and a pharmaceutical composition for improving brain functions comprising the triterpene compounds represented by the... Agent: Ronald R Santucci Frommer Lawrence & Haug

20070249714 - Method of treating skin requiring fractional resurfacing treatment: A treatment regimen for treating skin subject to fractional resurfacing procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070249713 - Prevention of retinopathy by inhibition of the visual cycle: The invention relates to compounds capable of inhibiting the visual cycle and/or dark adaptation and their use for treatment and prevention of non-degenerative retinal diseases with specific emphasis on the prevention and treatment of diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion, central retinal vein occlusion, open-angle glaucoma, veovascular... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070249716 - Illuminator for photodynamic therapy: An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic... Agent: Foley And Lardner LLP Suite 500

20070249717 - Preventive/therapeutic agent for visceral pain: The present invention provides an agent for the prophylaxis or treatment of visceral pain associated with gastrointestinal tract diseases, which contains lysine. Using the prophylactic or therapeutic agent, gastrointestinal tract diseases accompanying visceral pain, such as intestinal disorder, irritable bowel syndrome, functional dyspepsia, gastro esophageal disease, functional abdominal pain syndrome,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249718 - Stable gabapentin compositions: Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070249715 - Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective: Use of neboglamine, (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), of the racemate thereof or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of schizophrenia.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070249719 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070249720 - Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability: The present invention relates to a pharmaceutical composition comprising a thiourea derivative or its pharmaceutically acceptable salt, a cyclodextrin or its derivative; and a pharmaceutical formulation comprising same.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070249721 - Hair restorer: The object of the present invention is to provide a hair restorer which exhibits a stimulatory effect on hair restoration against hair loss, hair thinning, split ends, hair graying, etc., with higher stability and safety than those of known hair restorers containing 5-aminolevulinic acids as active components. By using 5-aminolevulinic... Agent: Morgan & Finnegan, L.L.P.

20070249723 - Methods for preparing sulfonamide compounds: e

20070249722 - Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070249724 - Method of inhibiting inflammatory pain: A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1RS,3RS,6RS)-6-dimethyl-aminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol compound, preferably in the form of a physiologically acceptable salt, such as the hydrochloride.... Agent: Crowell & Moring LLP Intellectual Property Group

20070249726 - Methods and compositions with trans-clomiphene: The present invention relates to the use of compositions comprising trans-clomiphene for treating wasting, especially a loss of muscle mass. The invention is also directed to methods for treating wasting in a patient with chronic obstructive pulmonary disorder. The present invention is also directed to methods for treating hypogonadism in... Agent: Howrey LLP

20070249725 - Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain: The invention encompasses novel pharmaceutical compositions and dosage forms of sympathetic adrenergic antagonists that are formulated for parenteral administration to a human. Also provided are methods of treating a human with the pharmaceutical compositions and dosage forms, and kits of the pharmaceutical compositions and dosage forms.... Agent: Duane Morris LLP

20070249727 - Compositions and kits useful for treatment of respiratory illness: The invention relates to a clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof. Also disclosed are kits comprising: a composition contained in a device; wherein said... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070249728 - Synergistic anti-inflammatory pharmaceutical compositions and methods of use: The invention provides a composition comprising a reduced isoalpha acid (RIAA) and isoalpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. The invention also provides a method of reducing inflammation by administering a composition comprising a reduced isoalpha... Agent: Simona Levi-minzi Mcdermott Will & Emery

20070249729 - Method of treating elevated plasma homocysteine levels in esrd patients: A method of treating elevated plasma total homocysteine levels (tHc) in subjects with end stage renal disease (ESRD) is disclosed, said treatment comprising the administration of sodium 2-mercaptoethylsulfonate (MESNA) immediately prior to, or concurrently with, performing hemodialysis on said patient.... Agent: Bereskin And Parr

20070249730 - Intravenous propofol emulsion compositions having preservative efficacy: The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble... Agent: Thorpe North & Western, LLP.

20070249731 - Abnormal cannabidiols as agents for lowering intraocular pressure: e

20070249732 - Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms): Certain biphenyl compounds, including 5-chloro-6-(4-hydroxyphenyl)-2-naphthalenol and 6-(4-hydroxy-phenyl)-2-naphthalene methanol are useful in the treatment of multiple sclerosis on the cellular level of the central nervous system through the protection of the patients' oligodendrocytes and neurons.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070249733 - High molecular substance beads having water-insoluble inorganic compounds encapsulated therein, their preparation method and use: The present invention relates to polymer beads having a water-insoluble inorganic compound encapsulated therein, and their preparation method and use. In the present invention, the water-insoluble inorganic compound which has limitations on its use because of the characteristic of precipitates in an aqueous solution is encapsulated in the polymer beads.... Agent: Buchanan, Ingersoll & Rooney PC

20070249734 - Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes: A method, composition and kit for detecting the presence of a phospholipid, such as phosphatidylserine, on a cell membrane is provided. A binding agent including lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin, is used to detect the presence... Agent: Law Office- Dineshagarwal. P.C.

20070249735 - Halide-free glucosamine-acidic drug complexes: A complex of glucosamine having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having a pKa of less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer... Agent: Law Office Of Jack Matalon

20070244069 - Method of palliating lower urinary tract infections by treatment with mannan oligosaccharides: Provided herein are methods of using mannan oligosaccharides, to treat, palliate, relieve, prevent and/or eliminate urinary tract infections of humans. A mixture of oligosaccharides derived from yeast cell walls is shown to reduce, eliminate and prevent the symptoms of UTI in patients.... Agent: David S. Dolberg

20070244030 - Method for assessing cancerous state: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Neurofilament3 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining... Agent: Sughrue Mion, PLLC

20070244031 - Methods and compositions for homozygous gene inactivation using collections of pre-defined nucleotide sequences complementary chromosomal transcripts: Methods and compositions for performing homozygous gene inactivation assays are provided. A feature of the subject methods is the use of a library of constructs that synthesize predefined nucleic acids, where each constituent predefined nucleic acid of the library is of known sequence that corresponds to a sequence of a... Agent: Bozicevic, Field & Francis LLP

20070244032 - Cancer cell targeting gene delivery method: The inventive chimeric ligand in the form of a fusion polypeptide of a single-chain antibody specific for Tag-72 surface antigen and GaLV envelope glycoprotein shows high transduction efficiency to cancer cells, specifically infects target cells and efficiently delivers a therapeutic gene. Accordingly, the inventive chimeric ligand can be effectively used... Agent: Sughrue Mion, PLLC

20070244034 - Glp-1 pharmaceutical compositions: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.... Agent: Leon R. Yankwich, Esq. Yankwich & Associatess, P.C.

20070244033 - Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc protein: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and... Agent: Bozicevic, Field & Francis LLP

20070244035 - Novel co-modulators of nuclear receptors and methods of detecting and treating steroid hormone-dependent diseases using same: Novel co-modulator proteins, designated ARAP3 polypeptides, for nuclear receptors, especially the androgen receptor, are described, which are useful in methods of detecting and treating steroid hormone-dependent diseases that are due to a deficiency of these co-modulator proteins. By measuring the levels of ARAP3 polypeptide expression in tissue samples from an... Agent: Striker, Striker & Stenby

20070244036 - Highly phosphorylated and sulfated recombinant factor ix: The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation,... Agent: Baxter Healthcare Corporation

20070244037 - Human chemokine hcc-1 polypeptides to improve stem cell transplantation: The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against... Agent: Jacobson Holman PLLC

20070244038 - Methods for treating lymphocyte-associated disorders by modulation of siglec activity: This disclosure relates to methods for modulating lymphocyte activity and/or proliferation by regulating the activity or expression of Siglec.... Agent: Buchanan, Ingersoll & Rooney LLP

20070244039 - Therapeutic agent composition and method of use: The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic... Agent: David R Preston & Associates Apc

20070244047 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070244042 - Antagonizing tgf-beta activity with various ectodomains of tgf-beta receptors used in combination or as fusion proteins: Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGFβ) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII... Agent: Robert W Strozier, P.l.l.c

20070244044 - Antimicrobial peptides: The present invention relates to a peptide comprising amino acids according to Formula (I): ((X)l(Y)m)n wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or... Agent: Speckman Law Group PLLC

20070244051 - Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia: Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence of hyperemia.... Agent: Allergan, Inc.

20070244049 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone: Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.... Agent: Nastech Pharmaceutical Company Inc

20070244046 - Identification and characterization of cancer stem cells and methods of use: A subpopulation of cancer stem cells expressing elevated levels of uPAR have been identified among a population of cancer cells. Methods are provided for treating proliferative disorders such as cancer by administering one or more uPAR inhibitors. Methods are likewise provided for predicting the likelihood of recurrence of a cancer,... Agent: Perkins Coie LLP

20070244040 - Livin-derived peptides, compositions and use thereof: The present invention relates to livin-derived peptides with pro-apoptotic activity. More specifically, the present invention provides peptides p30-Livin a and p28-Livin β, derived from Livin α and β, respectively, as well as compositions thereof. These herein described peptides display pro-apoptotic activity. Thus, another object of the present invention is the... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070244052 - Methods for identifying agonists or antagonists of cd200r signaling molecules and methods of using the same: The present invention provides methods for identifying agonists or antagonists of CD200R signaling. In addition, the present invention provides methods for treating patients suffering from CD200R-mediated medical conditions.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070244048 - Neuromedin u receptor agonists and uses thereof: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.... Agent: Merck And Co., Inc

20070244041 - Peptide yy analogues: Analogues of the peptide PYY (1-36) are described in which the tertiary structure of the peptide is preserved and stabilised particularly to enhance binding and activation of the Y2 receptor by the use of cross links or rigid bends in the peptide to constrain conformationally the positions of the N-terminal... Agent: Edwards Angell Palmer & Dodge LLP

20070244050 - Peptides as solubilizing excipients for transforming growth factor beta proteins: The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubility of proteins. The invention also relates to methods of resolubilizing a... Agent: Wyeth/finnegan Henderson, LLP

20070244043 - Recombinant e-selectin made in insect cells: The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070244045 - Treatment of acute respiratory distress syndrome: Patients suffering from acute respiratory distress syndrome or acute lung injury are treated by administering to the patients a therapeutically effective dosage of a surfactant that includes SP-B and phospholipid at a concentration of SP-B relative to concentration of phospholipid that is sufficient to produce detectable SP-B dependent activity.... Agent: Jaeckle Fleischmann & Mugel, LLP

20070244053 - Use of a cd40:cd154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection: Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070244054 - Peptides for use in treating obesity: Novel cyclic and linear peptides of the formula R1—X—X1—X2—X3—X4—X5—X6—X7—X8—X9—X10—X11—R2 are useful in the treatment of obesity are provided.... Agent: Novo Nordisk, Inc. Patent Department

20070244055 - Conjugates useful in the treatment of prostate cancer: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug... Agent: Merck And Co., Inc

20070244056 - Combination therapy with glatiramer acetate and riluzole: The subject invention provides a method of providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection comprising periodically administering to the subject an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzathiazole, wherein the amounts when taken together are effective to provide... Agent: Cooper & Dunham, LLP

20070244057 - Suppressing polyglutamine aggregation and toxicity: It has been discovered that CHIP suppresses polyglutamine aggregation and toxicity in transfected cell lines, primary neurons and a novel zebrafish model of disease. Accordingly, certain embodiments of the present invention provide methods for decreasing the formation of an inclusion or aggregation of a protein or for increasing the solubility... Agent: Viksnins Harris & Padys Pllp

20070244058 - Galactose derivative, drug carrier and medicinal composition: The present invention relates to a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention also relates to a galactose... Agent: Darby & Darby P.C.

20070244062 - Antisense compounds targeted to connexins and methods of use thereof: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell... Agent: Duane Morris LLP

20070244063 - Bv8 nucleic acids and polypeptides with mitogenic activity: The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided.... Agent: Merchant & Gould PC

20070244065 - Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer: The present invention relates to a method of treating cancer in a patient comprising administering an effective amount of a Survivin antisense oligonucleotide in combination with an effective amount of gemcitabine hydrochloride.... Agent: Eli Lilly & Company

20070244061 - Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondisn) and/or wnt: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The... Agent: Moore & Van Allen PLLC

20070244067 - Devices and processes for distribution of genetic material to mammalian limb: A process is described for the delivery of a therapeutic polynucleotide to limb muscle tissue suffering from or potentially suffering from Muscular Dystrophy. The polynucleotide is inserted into a mammalian limb vessel such as an artery. Delivery efficiency and distribution is enhanced by combining injection of a solution containing the... Agent: Mirus Corporation

20070244059 - Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation: The present invention relates to the use of the cyclic dinucleotide c-di-GMP and cyclic dinucleotide analogues thereof in a method for attenuating virulence of a microbial pathogen or for inhibiting or reducing colonization by a microbial pathogen. This method further inhibits microbial biofilm formation and is capable of treating bacterial... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070244066 - Method for preventing or treating neuropathic pain: The present invention is a method for preventing or treating neuropathic pain. Using an agent to decrease the expression or activity of Toll-like receptor 4 (TLR4), behavioral hypersensitivity is attenuated thereby preventing or treating neuropathic pain in a subject in need of such treatment.... Agent: Licata & Tyrrell P.C.

20070244064 - Methods and compositions to induce antitumor response: The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention invention is induces multiple stages of dendritic cell differentiation, activation and migration in vivo using... Agent: Townsend And Townsend And Crew, LLP

20070244060 - Therapeutic agent for autoimmune disease: The present invention provides an apoptosis-inducing agent or a therapeutic agent for autoimmune diseases, comprising a substance that induces ER stress; and a method for inhibiting the proliferation of cells, wherein the cells (for example, synoviocytes) are treated with the inducing agent.... Agent: Dickstein Shapiro LLP

20070244068 - Degradation-resistant mononucleoside phosphate compounds: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from... Agent: Howery LLP

20070244070 - Use of organic glucosamine salts: The present invention relates to the use of an organic glucosamine salt selected from glucosamine glucuronate, glucosamine ascorbate, glucosamine malate, glucosamine hydrogen malate, glucosamine citrate, glucosamine hydrogen citrate, and glucosamine dihydrogen citrate for the preparation of a medicament for the treatment of arthrosis and inflammation and pain associated with arthrosis.... Agent: Sughrue Mion, PLLC

20070244072 - 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof: Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analogs thereof characterized by the presence of a 3′-hydroxypropylidene moiety at C-2 and the presence of an abbreviated alkyl side-chain free of any hydroxyl... Agent: Quarles & Brady LLP

20070244071 - Treatment of proliferative diseases: wherein * is ═C or ═O, R1 and R2 independently represent substituted or unsubstituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silythio, carboxyl, carbonyl,... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070244073 - Pesticidal mixtures: The invention relates to a pesticidal composition comprising as active ingredient a mixture consisting of one antranil-amide compound (A) as defined in the patent claims and at least one compound (B) as defined in the patent claims, to a process for the preparation of and to the use of such... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070244074 - Stable parenteral formulation of fosphenytoin sodium: A more stable formulation of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester, wherein the composition is made more stable by using a solution essentially free of tromethamine.... Agent: Blank Rome LLP

20070244075 - Isoflavonoid prodrugs, compositons thereof and therapeutic methods involving same: Phosphate esters of isoflavonoid compounds are prepared for use as prodrugs, medicaments and in formulations, drinks and foodstuffs.... Agent: Sughrue Mion, PLLC

20070244076 - Site and rate selective prodrug formulations of d609 with antioxidant and anticancer activity: Compounds that are heteroatom substituted alkyl derivatives of tricyclodecan-9-yl-xanthogenate, and pharmaceutical compositions of these compounds, are disclosed. Methods of treating a disease or disorder in a subject and methods of protecting normal tissues in a subject from toxicity associated ionizing radiation or chemotherapy using compositions comprising these novel compounds are... Agent: Fulbright & Jaworski L.L.P.

20070244077 - Composition and method of treating peripheral neuropathy: A method of treating diabetic neuropathy in a subject includes administering to a subject having diabetes or at risk of diabetes a therapeutically effective amount of a pharmaceutical composition comprising at least one of sulfasalazine or a composition including 5-aminosalicyclic acid and sulfapyridine.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070244078 - Methods for treatment, modification and management of pain using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline: Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical... Agent: Jones Day

20070244079 - Preventive/remedy for allergic diseases: The present invention provides a prophylactic/therapeutic agent for an allergic disease caused by Th2 cell-polarized activation, which comprises at least one kind selected from a branched amino acid, glycine, serine, arginine, a keto acid thereof and a salt thereof. Because the prophylactic/therapeutic agent of the present invention produces almost no... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070244080 - Method for treatment of inflammatory disorders using triptolide compounds: Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-β production in a patient afflicted with such a disorder.... Agent: Perkins Coie LLP

20070244081 - Triterpene quaternary salts as biologically active surfactants: The invention provides novel compounds that are quaternary amine derivatives of betulin and other triterpenes. The compounds have antibacterial, antifungal, and surfactant properties.... Agent: Schwegman, Lundberg & Woessner, P.A.

20070244082 - Anticancer agent: This catenate compound is a type of compound referred to as amide [2] catenane, and has a structure in which two molecular rings Linked to each other like a chain are not bonded to each other by covalent bonding. The shape of the molecule can be easily changed and the... Agent: Wolff Law Office, PLLC

20070244083 - Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection: A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.... Agent: Foley & Lardner LLP

20070244085 - Injectable or orally deliverable formulations of azetidine derivatives: The invention concerns injectable or orally deliverable binary or ternary formulations of azetidine derivatives. The azetidine derivatives used in the inventive pharmaceutical compositions can be represented by the general formulae (Ia) or (Ib), wherein Ar is an aromatic or heteroaromatic group optionally substituted by one or more among (C1-C4)alkyl, halogen,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070244084 - Method and intermediates for the preparation of derivatives of n (1-benzhydrylazetidin-3-yl)-n-phenylmethylsulfonamide: The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070244087 - 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof: The invention relates particularly to 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof as a medicament, particularly as anti-cancer agents.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070244089 - 2- arylmethylazetidine carbapenem derivatives and preparation thereof: A 2-arylmethylazetidine carbapenem derivative of formula (I) or a pharmaceutically acceptable salt thereof exhibits a wide spectrum of antibacterial activities against Gram-positive and Gram-negative bacteria and excellent antibacterial activities against resistant bacteria such as methicillinresistant Staphylococcus aureus (MRSA) and quinolone-resistant strains (QRS).... Agent: Anderson, Kill & Olick, P.C.

20070244086 - 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke,... Agent: Fish & Richardson P.C.

20070244088 - New pyridine analogues ii: e

20070244091 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070244090 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase: p

20070244092 - Therapeutic compounds:

20070244093 - Quetiapine formulations: The invention provides novel dosage forms of quetiapine and its salts, particularly quetiapine hemifumarate including wax dosage forms, press-coat dosage forms, and sprinkle dosage forms, and other novel dosage forms. The invention also provides sustained release and pulsed release dosage forms of quetiapine and its salts. Methods of making novel... Agent: Cantor Colburn, LLP

20070244094 - Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol: The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia... Agent: Philip S. Johnson Johnson & Johnson

20070244095 - Compounds and method for treating dyslipidemia: e

20070244096 - Fused bicyclic nitrogen-containing heterocycles: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.... Agent: Leydig Voit & Mayer, Ltd

20070244099 - Cgrp antagonists: m

20070244100 - Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them: wherein any R3 to R6 group having an aryl or heteroaryl moiety can optionally be substituted on the aryl or heteroaryl moiety with 1 to about 5 substituents, independently, selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C6 alkyl, and C1-C6 alkoxy. Methods of making these compounds as... Agent: Woodcock Washburn LLP/wyeth

20070244098 - Dual small molecule inhibitors of cancer and angiogenesis: The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.... Agent: University Of Virginia Patent Foundation

20070244097 - Nicotinic acetylcholinereceptor ligands: Acetylcholine receptor ligands of formula I wherein D, E and G are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070244101 - Novel compositions and methods of treatment of type ii diabetes and hypertension: The subject invention relates to a composition and method for treating a patient employing co-formulation or co-administration of a thiazolidinedione (TZD) and a diuretic.... Agent: Accu-break Technologies, Inc.

20070244102 - Combination of dermaciclane and opoids as analgesics: The invention relates to a combined analgesic pharmaceutical composition which comprises as component: A) (1R,2S,4R)-(−)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7-7-trimethylbicyclo[2.2.1]heptane or a pharmaceutically acceptable acid addition salt thereof and as component B) morphine, an opioide type analgesic and/or a non-opioide type analgesic in admixture with suitable pharmaceutical carriers and/or auxiliary agents. Deramciclane increases the analgesic... Agent: K.f. Ross P.C.

20070244103 - Novel compounds having an anti-bacterial activity: e

20070244104 - Thiazolyl-dihydro-quinazoline:

20070244105 - Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070244106 - Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070244107 - Method of treating atherosclerosis, dyslipidemias and related conditions: A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that... Agent: Merck And Co., Inc

20070244108 - Phenylsulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase inhibitors: m

20070244109 - Pyrrole based inhibitors of glycogen synthase kinase 3: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in... Agent: Chiron Corporation Intellectual Property - R440

20070244110 - Treatment of prostate cancer, melanoma or hepatic cancer: The present application describes a method of treating prostate cancer, melanoma or hepatic cancer in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the heterocyclic compound represented by Formula I or its pharmaceutically acceptable salt:... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070244111 - Pyrazolopyrimidines: e

20070244113 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070244114 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070244112 - Novel tetrahydropyridothiophenes: s

20070244115 - Amino-halogen-imidazopyridines as proton pump inhibitors:

20070244116 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20070244118 - Cyclic amide derivative, and its production and use: wherein R1 represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X1 represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y1 represents —C(O)—, —S(O)—... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070244117 - Novel hydroxamic acid esters and pharmaceutical use thereof: e

20070244119 - 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20070244120 - Inhibition of raf kinase using substituted heterocyclic ureas: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.... Agent: Millen, White, Zelano & Branigan, P.C.

20070244122 - Derivatives of sulindac, use thereof and preparation thereof: Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.... Agent: Connolly Bove Lodge & Hutz LLP

20070244121 - Synergistic fungicidal compositions: A method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination of components A) and B) in a synergistically effective amount, wherein component A) is a compound of formula (I), wherein... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070244123 - Heterocycle-carboxamide derivatives as raf kinase inhibitors: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine or cardiac hypertrophy.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070244125 - 5-amido-indole-2-carboxamide derivatives: m

20070244124 - Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline: The present invention provides novel salt and hydrate crytal forms of (2R)-anti-5- {3-[4 -(10,11-difluoromethano-dibenzosuber-55yl]-2-hydroxypropoxy}quinoline 2.5 hydrochloride.... Agent: Knobbe Martens Olson & Bear LLP

20070244126 - Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor: Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20070244127 - Stable dosage form of phenylalanine derivatives: The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and the use thereof as urokinase inhibitors, particularly for the treatment of malignant tumors and tumoral metastases.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070244128 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070244129 - Process for the preparation of an isopropanol solvate of a glucokinase activator: Provided is a process for the preparation of 2(R)-(3-Chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxo-cyclopentyl)-N-pyrazin-2-yl-propionamide and its isopropanol solvate as a glucokinase activator which increases insulin secretion in the treatment of, for example, type II diabetes.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070244131 - 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists: wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070244130 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.... Agent: Genomics Institute Of The Novartis Research Foundation

20070244132 - Fused heterocyclic compound: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070244133 - Thienopyrimidines and thiazolopyrimidines for use in medicine: The use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, X4, Ra, p, R1, Z, Y, R2, R3 and R4 are as defined in the specification, in the preparation of a medicament for the treatment of C—C chemokine mediated conditions,... Agent: Morgan Lewis & Bockius LLP

20070244134 - Selective antagonists of a2a adenosine receptors: e

20070244135 - Sulfonamides: Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070244136 - Quinazoline derivatives: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20070244137 - Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes: Pharmaceutical compositions containing new molecules capable of inhibiting acetylcholinesterase, thus being useful in the treatment of pathologies associated to cholinergic transmission, such as memory related disorders, neurodegenerative disorders such as Alzheimer's Disease, Miastenia Gravis or in the treatment of intoxications induced by chemical agents of central action The production processes... Agent: Smith, Gambrell & Russell

20070244140 - Anilino-pyrimidine phenyl and benzothiophene analogs: a

20070244139 - Indole derivatives or benzimidazole derivatives for modulating ikb kinase: The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of IκB kinase comprising administering such compounds.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20070244138 - Mercaptoimidazoles as ccr2 receptor antagonists: a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C1-4alkyl) amino, nitro, aryl or aryloxy; R3 represents... Agent: Philip S. Johnson Johnson & Johnson

20070244141 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070244142 - Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070244143 - Modulation of neurogenesis by nootropic agents: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or... Agent: Townsend And Townsend And Crew, LLP

20070244144 - Process for the preparation of desloratadine: The present invention relates to an improved process for the preparation of Form 1 of desloratadine essentially free of Form 2. The invention also relates to Form 1 of desloratadine substantially free of Form 2, process for its preparation, pharmaceutical composition comprising it and its method of use for the... Agent: Ranbaxy Inc.

20070244145 - Cyclic amine compound: wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by... Agent: Sughrue Mion, PLLC

20070244146 - Thienopyridines as ikk inhibitors: e

20070244147 - Therapeutic agent for schizophrenia: Provision of a pharmaceutical agent useful for the treatment of schizophrenia. As a solving means, a therapeutic agent for schizophrenia containing a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative, an enantiomer thereof, an acid addition salt thereof or a hydrate or solvate thereof as an active ingredient is provided.... Agent: Leydig Voit & Mayer, Ltd

20070244148 - Imidazo 4,5-c pyridine compounds and methods of antiviral treatment: o

20070244150 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070244149 - Tropane analogs and methods for inhibition of monoamine transport: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the... Agent: Edwards Angell Palmer & Dodge LLP

20070244151 - Opiate intermediates and methods of synthesis: Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided.... Agent: Mallinckrodt Inc.

20070244153 - Diamine derivative, process of preparation thereof, and fungicide comprising diamine derivative as an active ingredient: [wherein R1 is substituents such as an alkyl group having 1 to 6 carbon atoms and the like, R2 and R5 are each independently substituents such as hydrogen atom, an alkyl group having 1 to 6 carbon atoms and the like, R3 and R4 are each independently substituents such as... Agent: Buchanan, Ingersoll & Rooney PC

20070244152 - Use of an nk3 antagonist for the treatment of bipolar disorders: This invention relates to the use of the NK3 receptor antagonist talnetant [(S)—(−)—N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide] for treating bipolar disorder.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070244155 - Bicyclic carboxylic acid derivatives useful for treating metabolic disorders: i

20070244154 - Substituted tricyclic benzimidazoles:

20070244156 - Sulfonylamino-acetic acid derivatives: The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor... Agent: Dickstein Shapiro LLP

20070244157 - Crystalline form of a benzimidazole-carboxamide medicinal compound: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.... Agent: Theravance, Inc.

20070244158 - Piperdine compound and process for preparing the same: R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070244159 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O'brien

20070244160 - 6-11 bicyclic ketolide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070244161 - Novel mercaptophenyl naphthyl methane compounds and synthesis thereof: Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma,... Agent: Buchanan, Ingersoll & Rooney PC

20070244162 - Substituted aromatic heterocyclic compounds as fungicides: v

20070244163 - Fused ring thrombin receptor antagonists: represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070244164 - Pyridone sulfonamides and pyridone sulfamides as mek inhibitors: This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070244165 - Method for identifying and producing effectors of calmodulin-dependent peptidyl-prolyl cis/trans isomers: The present invention relates to a method for identifying and producing effectors of peptidyl-prolyl cis/trans isomerases which can be activated by calmodulin. The invention also relates to the use of the identified effectors for the production of medicaments and to screening methods and kits.... Agent: Kagan Binder, PLLC

20070244166 - Pre-mixed, ready-to-use iv bolus compositions and methods of use: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Townsend And Townsend And Crew LLP

20070244167 - Method for purificaion of amlodipine free base: Summary A method for the purification of the deprotected free amlodipine base, present in the reaction mixture following deprotection of an N-protected amlodipine compound, whereby (i) the reaction mixture containing the deprotected amlodipine free base, optionally after a preceeding filtration, is evaporated to dryness, or the solvent removed from the... Agent: Daniel A Scola Hoffmann & Baron

20070244168 - Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound: The present invention describes a new one ritonavir analogous compound that presents significantly superior activity in inhibition of HIV protease. There are also described the usage of the ritonavir analogous compound of the present invention or salt, ester or prodrug thereof as well as the usage of the compound and... Agent: Birch Stewart Kolasch & Birch

20070244169 - Glucokinase activators: e

20070244171 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070244172 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20070244170 - Novel pyrrole derivatives with angiotensin ii antagonist activity: Compounds which may be represented by the general formula (I) shown below and in which: R1 is a group independently selected from among: CHO, —COOH, —CH2OH R2 is hydrogen or a linear or branched C1-C6 alkyl group R3 is hydrogen or a halogen group selected from among Cl and Br... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070244173 - 6,7-dihydroxy-8-phenyl-3,6,7,8-tetrahydro-chromeno [7,8-d] imidazole derivatives and their use as gastric acid secretion inhibitors: m

20070244174 - Chemical inhibitors of soluble adenylyl cyclase (sac): The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl... Agent: Kenyon & Kenyon LLP

20070244175 - Phytonutrient compositions from mushrooms or filamentous fungi and methods of use: This invention is directed to treating disease states or conditions associated with the treatment and prevention of neurodegeneration and neurodegenerative disease states, and treatment of radiation damage. The invention relates to novel phytonutrient compositions and compounds comprising L-ergothioneine and/or selenium. The invention also provides a method of administering these compositions... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20070244176 - Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1h-pyrazol-3'-o-beta-d-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070244177 - Enzyme inhibitors: e

20070244178 - Process for the preparation of indazolyl ureas that inhibit vanilloid subtype1 (vr1) receptors: The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1).... Agent: Robert Deberardine D-377/ap6a-1

20070244179 - Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070244181 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat... Agent: Glaxosmithkline Corporate Intellectual Property-uw2220

20070244182 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat... Agent: Glaxosmithkline Corporate Intellectual Property

20070244180 - Substituted indole derivatives: Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.... Agent: Cephalon, Inc.

20070244183 - Isoindoline compounds and methods of making and using the same: The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.... Agent: Jones Day

20070244184 - Glycosidase inhibitors and methods of synthesizing same: The compounds of the present invention relate to chain-extended and chain-modified analogues of salacinol, including embodiments where the sulfate moiety has been substituted with a carboxylate or phosphate moiety. In other embodiments the sulfate moiety has been shifted by one carbon atom in the zwitterionic structure. In another embodiment the... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20070244186 - 4, 7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses: A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.... Agent: Hunton & Williams LLP Intellectual Property Department

20070244185 - Crystal form and pharmaceutical compositions of (+)-r-zileuton: Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070244187 - Intermediates for the preparation of halichondrin b: The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).... Agent: Clark & Elbing LLP

20070244188 - Anti-first-pass effect compounds: Compositions, methods, etc. for addressing the first-pass effect.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070244189 - Antioxidant material, anti-deterioration agent and food or beverage: An antioxidant material of the present invention contains flavonoid aglycon and vitamin C. The flavonoid aglycon is eriodictyol and/or diosmetin obtained by treatment of a raw material containing flavonoid glycoside derived from lemons, limes, or sudachis to form the aglycones thereof. It is preferred that this antioxidant material be produced... Agent: Posz Law Group, PLC

20070244190 - Neobritannilactone b and acetyl neobritannilactone b: Provided herein are methods of inducing apoptosis in cancer cells using neobritannilactone B (NAB) or acety neobritannilactone B (ANAB). Also provided are pharmaceutical compositions and methods for using NAB or ANAB to prevent or treat cancer in a mammal. Exemplary cancers include, for example, colon cancer, leukemia, and gastric cancer.... Agent: Jones Day

20070244191 - Strontium salts of sulphonic acids, a process for their preparation and pharmaceutical compositions containing them: o

20070244192 - Plant seed oils containing polyunsaturated fatty acids: Disclosed are plants that have been genetically modified to express a PKS-like system for the production of PUFAs (a PUFA PKS system), wherein oils produced by the plant contain at least one PUFA produced by the PUFA PKS system and are free of the mixed shorter-chain and less unsaturated PUFAs... Agent: Sheridan Ross PC

20070244193 - Intramuscular antiviral treatments: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.... Agent: Viksnins Harris & Padys Pllp

20070244194 - Carboxamido opioid compounds: This invention is directed to carboxamido opioid compounds pharmaceutically useful as agents for treating or modulating a central nervous system disorder and methods for treating or modulating a central nervous system disorder.... Agent: Philip S. Johnson Johnson & Johnson

20070244195 - Treatment methods with peroxides and tertiary amines: This invention relates to methods of increasing the efficacy of peroxides such as benzoyl peroxide in the treatment of skin conditions such as acne. In a preferred embodiment, the invention relates to methods of increasing radicals formed by peroxides on/in the skin, more specifically near/in the comedone, for topical use... Agent: Macmillan Sobanski & Todd, LLC

20070244196 - Prostaglandin f2alpha derivative-containing product: The present invention provides a resin container in which an aqueous liquid preparation containing a prostaglandin F2α derivative having at least a fluorine atom in its molecule can be stored stably for a long period of time. By storing the aqueous liquid preparation containing the prostaglandin F2α derivative having at... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070244197 - Antibacterial agents: e

20070244198 - Carboxylic derivatives: The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.... Agent: Fish & Richardson PC

20070244199 - Anti-mycobacterial formulation: The invention provides anti-microbial compositions, including compositions with inhibitory activity against mycobacteria. The invention further provides methods for treating microbial infections, including the treatment of mycobacterial infection and diseases such as tuberculosis.... Agent: Townsend And Townsend And Crew, LLP

20070244200 - Method for triggering angiogenic response: The use of known chemical anadamide compounds and its analog methanandamide as a molecule to evoke angiogenic responses as measured by the increase in cord formation and increase in branching points or cord junction numbers A rabbit aortic endothelial cell is used as a model and in in vitro cord... Agent: Charles Edison Smith

20070244201 - Cyclopropanes with central nervous system activity: Disclosed are aromatic cyclopropane compounds with CNS activity. These compounds can be used for alleviating symptoms of CNS disorders.... Agent: Hodgson Russ LLP The Guaranty Building

20070244202 - Ampk activator: The present invention relates to an AMPK activator containing resveratrol as an active ingredient. The present invention provides an AMPK activator containing, as an active ingredient, an ingredient contained in a naturally occurring material which has been consumed as a food or beverage for a long period of time, which... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070244203 - Controlled-release composition for topical application and a method of delivering an active agent to a substrate: A controlled-release composition for topical application to a substrate includes an oil-in-water emulsion and an active agent incorporated into the oil-in-water emulsion. The oil-in-water emulsion is substantially free of lipophilic solvent and is formed by mechanical inversion of a water-in-oil emulsion. The water-in-oil emulsion includes a silicone component, a surfactant,... Agent: Howard & Howard Attorneys, P.C.

20070238645 - Regulators of the non-genomic action of progesterone and methods of use: A progesterone regulator capable of modulating the non-genomic action of progesterone and methods of using the progesterone regulator are described. The progesterone regulator is useful for attenuating progesterone's inhibition of apoptosis and for the treatment of patients having a progesterone-responsive tissue disease such as endometriosis or cancer, particularly ovarian cancer.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070238679 - Articles having localized molecules disposed thereon and methods of producing same: Methods of producing substrates having selected active chemical regions by employing elements of the substrates in assisting the localization of active chemical groups in desired regions of the substrate. The methods may include optical, chemical and/or mechanical processes for the deposition, removal, activation and/or deactivation of chemical groups in selected... Agent: Pacific Biosciences Of California, Inc.

20070238692 - Compositions and methods for treating diseases associated with t-box and n-myc: The invention herein provides a mode of treating a disease associated with the regulation of T-Box and N-Myc gene which includes cancers and heart disease in human and other subjects by identifying and administering a compound which modulates T-Box or N-Myc function. The invention also provides polynucleotides, polypeptides, vectors, cells,... Agent: Biotactica, LLC

20070238695 - Synergistic method for the treatment of joint dysfunction using s-adenosyl-methionine and a patented mixture of cetylated fatty acids: Life Science's breakthrough SAM-e (S-Adenosyl-Methionine)/Celadrin™ (a patented mixture of cetylated fatty acids) combination is a two-pronged approach to the treatment of arthritis. The Celadrin™ helps to restabilize the balance of the catabolism and production of cartilage components, and the SAM-e actually helps regenerate cartilage that has already been destroyed. By... Agent: Yochanan Bulke

20070238703 - 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds with a 1,1-dimethylpropyl side chain: This invention discloses 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain, and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238705 - 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof: Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238706 - 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof: Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238702 - 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof: Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238707 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain... Agent: Synnestvedt & Lechner, LLP

20070238638 - Bak promoter expression system: The present invention provides polynucleotides which regulate the expression of a gene involved in apoptosis. Also provided are methods for identifying agents that modulate expression of a gene involved in apoptosis.... Agent: Sheridan Ross PC

20070238640 - Inhibitors of the interaction between hmgb polypeptides and toll-like receptor 2 as anti-inflammatory agents: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070238639 - Telomerase expression repressor proteins and methods of using the same: Telomerase repressor proteins and nucleic acid compositions encoding the same are provided. The subject repressor proteins bind to a repressor site in the TERT minimal promoter, e.g., a Site C site, and thereby inhibit TERT expression. Also provided are methods of modulating, e.g., inhibiting or enhancing, TERT expression. The subject... Agent: Bozicevic, Field & Francis LLP

20070238646 - Axmi-003, a delta-endotoxin gene and methods for its use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Alston & Bird LLP

20070238644 - Human chemokines ckbeta-4 and ckbeta-10/mcp-4: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070238648 - Methods and compositions employing a novel stearoyl-coa desaturase-hscd5: A cDNA encoding a novel human stearoy-CoA desaturase (dubbed “hSCD5”) as well as vectors and cells comprising such polynucleotide are disclosed. Also described arc assay methods for determining the ability of small molecules and other chemical agents to increase or decrease he enzymatic activity and/or gene expression level of hSCD5... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan,

20070238647 - Methods for treating prostate cancer: Methods are provided for treating prostate cancer, preventing or slowing proliferation of cells of prostate origin, preventing prostate cancer in a patient at risk of contracting prostate cancer, preventing or inhibiting an upregulation of the cell cycle in prostate-derived cells in a patient, and decreasing the level of prostate-specific antigen... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070238643 - P62 as a risk determinant for metabolic syndrome: The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070238641 - Pharmaceutical combined preparation containing a therapeutic protein: A pharmaceutical combined preparation containing a therapeutic protein having SH-groups which are nitrosated and a compound containing thiol groups and having an average molecular weight of at most 10.000.... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070238642 - Production of vascular endothelial cell growth factor and dna encoding same: DNA isolates coding for a vascular endothelial cell growth factor may be used to produce the protein via recombinant expression systems. Such protein is useful therapeutically to treat conditions in which a selective action on the vascular endothelial cells, in the absence of excessive connective tissue proliferation, is desirable.... Agent: Genentech, Inc.

20070238649 - Agents for regulating adiponectin receptor expression: The present inventors revealed by using fasted and refed mice, that AdipoR1/R2 is a regulator of metabolic sensitivity to nutritional conditions and insulin. They showed that mRNA level of AdipoR1/R2 increased by STZ treatment, and that this increase was restored by insulin. The present inventors confirmed in vitro that insulin... Agent: Medlen & Carroll

20070238653 - Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070238652 - Neutralization of bacterial spores: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., a lantibiotic-based spore decontaminant (e.g., comprising nisin)) and methods of neutralizing (e.g., killing or inhibiting growth or inhibiting germination of) bacteria (e.g., cells and spores). For example, the present invention provides nisin-based compounds... Agent: Medlen & Carroll, LLP

20070238651 - Nucleic acids and proteins of a rat ganglioside gm1-specific alpha1-2fucosyltransferase and uses thereof: A rat ganglioside GM1-specific α1→2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific α1→2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific α1→2fucosyltransferase with... Agent: Townsend And Townsend And Crew, LLP

20070238650 - Polymer-conjugated glycosylated neublastin: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of... Agent: Fish & Richardson P.C.

20070238654 - Compstatin and analogs thereof for eye disorders: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent.... Agent: Choate, Hall & Stewart LLP

20070238664 - 70 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070238665 - Fc variants having decreased affinity for fcyriic: The present invention relates to Fc variants having decreased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070238656 - Functionalized poly(ethylene glycol): wherein X is CH3, CN or H; Y is O, NR1, or S; L is a linking group or spacer; FG is a functional group; n is greater than 4 and less than 1000; and wherein R1 and R2 are independently selected from substituted or unsubstituted alkyl, aryl, or heteroyl.... Agent: Paul Leipold Eastman Kodak Company

20070238657 - Human fgf-21 gene and gene expression products: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods... Agent: Novartis Vaccines And Diagnostics Inc.

20070238658 - Il-17a and il-17f antagonists and methods of using the same: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are... Agent: Zymogenetics, Inc. Intellectual Property Department

20070238660 - Light activated antiviral materials and devices and methods for decontaminating virus infected environments: A method of inactivating viruses, articles for inactivating viruses and methods of manufacture of such articles are disclosed. Singlet oxygen generating dyes are attached to a substrate. Upon exposure to light, singlet oxygen is generated to inactivate viruses present. In a preferred embodiment, more than one dye is used. If... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070238655 - Methods of using gelsolin to treat or prevent bacterial sepsis: Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipopolysaccharide (LPS) endotoxins released from gram-negative bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds LPS from various bacteria with... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070238661 - Substance p treatment for hepatitis c: Substance P treatment has been demonstrated to be efficacious in a human Hepatitis C patient. Fibrosis of the liver is very damaging to long-term survival with Hepatitis C disease. Substance P treatment also has been demonstrated to preserve fibrinogen levels in the body.... Agent: Mark L. Witten, Ph. D.

20070238662 - Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation: The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food... Agent: Potter Anderson & Corroon LLP Attn: Kathleen W. Geiger, Esq.

20070238663 - Use of hmgb1 to promote stem cell migration and/or proliferation: It is described a method to promote stem cell migration and/or proliferation in cell culture or in vivo comprising the step of exposing such cells to an effective amount of the HMGB1 protein or its active fragment.... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070238659 - Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids: The present invention involves the preparation of vascular endothelial growth factor (VEGF) antagonist molecules comprising variant VEGF polypeptides which are capable of binding to and occupying cell surface VEGF receptors without inducing a VEGF response, thereby antagonizing the biological activity of the native VEGF protein. Specifically, the variant VEGF polypeptides... Agent: Merchant & Gould PC

20070238667 - Compositions for treatment of cancer: Synthetic peptides containing an ankyrin repeat-like motif or portion thereof and mimetics thereof which interact with synuclein-gamma (SNCG) and reduce SNCG-mediated resistance of SNCG-expressing cancer cells to treatment with anticancer drugs or inhibit tumorigenesis and cancer cell proliferation are provided. Compositions containing these peptides, portions thereof or mimetics thereof are... Agent: Kathleen A. Tyrrell Licata & Tyrell P.C.

20070238666 - Peptides selectively lethal to malignant and transformed mammalian cells: The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably... Agent: Dilworth & Barrese, LLP

20070238669 - Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only... Agent: Louis J. Wille Bristol-myers Squibb Company

20070238668 - Methods of using gelsolin to treat or prevent bacterial sepsis: Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipoteichoic acid (LTA) toxins released from gram-positive bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds to and neutralizes LTA... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20070238670 - Novel compositions and methods for promoting, inhibiting and detecting protein entry into cells: In vitro delivery of the diphtheria toxin (DT) catalytic (C) domain from the lumen of purified early endosomes to the external milieu requires the addition of both ATP and a cytosolic translocation factor (CTF) complex. The results presented here demonstrate that β-COP plays an essential role in the cytosolic release... Agent: Clark & Elbing LLP

20070238671 - Isopeptide gap junction modulators: The invention relates to isopeptides capable of modulating intracellular gap junctional communication. The invention further relates to methods of using the isopeptides to maintain or enhance such communication. In one aspect, the isopeptides are antiarrhythmic isopeptides which target the same cells targeted by AAP, AAP10, HP5, and/or functional analogs thereof,... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20070238672 - Co-administration of adenosine a1 receptor antagonists and anticonvulsants: Disclosed herein are pharmaceutical compositions that include an AA1RA, or a salt, ester, amide, metabolite, or prodrug thereof, and an anticonvulsant agent. Also disclosed are methods of treating patients suffering from congestive heart failure, methods of improving renal function, and methods of restoring renal function comprising the step of administering... Agent: Knobbe Martens Olson & Bear LLP

20070238673 - Ceramide derivatives as modulators of immunity and autoimmunity: α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are... Agent: Kenyon & Kenyon LLP

20070238674 - Tra combination therapies: x

20070238684 - Aav scleroprotein, production and use thereof: The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.... Agent: Clark & Elbing LLP

20070238685 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or... Agent: Dla Piper US LLP Attn: Patent Group

20070238693 - Genetic modification of the lung as a portal for gene delivery: The present invention relates to methods for treatment of systemic disorders using the lung as a depot organ for transgene delivery. Transfection of the pulmonary epithelium, particularly the deep alveolar cells, or pulmonary endothelial cells, is achieved via local administration of a transgene delivery vector to the lung. The transfected... Agent: Genzyme Corporation Legal Department

20070238682 - Heat shock rna and its use in activation of heat shock transcription factor and treatment of cancer, inflammation, ischemia, neurodegeneration, age-related diseases, hiv infection, deafness, and related disorders: The present invention provides a novel RNA, designated herein as the “HSR1” (Heat Shock RNA), and its use together with translation elongation factor eEF1A in activation of heat shock transcription factor HSF. The invention further provides the use of HSR1 for generation of novel therapeutics for the treatment of cancer,... Agent: Darby & Darby P.C.

20070238686 - Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to grb2 or crk1: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein... Agent: Fulbright & Jaworski L.L.P.

20070238691 - Inhibition of hiv replication and expression of p24 with eif-5a: The present invention relates to methods of inhibiting the replication of the HIV virus by providing siRNA or antisense polynucleotides of eIF-5A1. The present invention also provides methods of inhibiting expression of p24 with siRNA or antisense polynucleotides of eIF-5A1.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070238678 - Methods and compositions for inhibition of innate immune responses and autoimmunity: The invention provides immunoregulatory polynucleotides and methods for immunoregulation of individuals using the immunoregulatory polynucleotides.... Agent: Morrison & Foerster LLP

20070238683 - Modified and stabilized gdf propeptides and uses thereof: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders... Agent: Wyeth/finnegan Henderson, LLP

20070238681 - Modulation of ace2 expression: Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20070238687 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Isis Pharmaceuticals Inc

20070238688 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Isis Pharmaceuticals Inc

20070238689 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Isis Pharmaceuticals Inc

20070238690 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.... Agent: Isis Pharmaceuticals Inc

20070238677 - Pharmaceutical composition containing hshrd3: The present invention provides a pharmaceutical composition containing a substance which inhibits the proliferation of synovial tissue or synovial cells and the interleukin-6 production. It also provides a pharmaceutical composition for inhibiting the proliferation of synovial tissue or synovial cells and the interleukin-6 production, which is useful for diagnosing and... Agent: Dickstein Shapiro LLP

20070238676 - Polynucleotides for reducing respiratory syncytial virus gene expression: This invention pertains to polynucleotides, such as small interfering RNA (siRNA), useful for reducing the expression of respiratory syncytial virus (RSV) genes within a subject; and methods for treating a patient suffering from, or at risk of developing, an RSV infection by administering such polynucleotides to the subject.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070238675 - Stem cell beacon: A stem cell-attracting chemokine is expressed in damaged tissue using a stimulus-responsive vector system. The stimulus can be a physiological stimulus associated with cell injury, such as hypoxia or elevated glucose levels, for example. Expression of the chemokine increases the trafficking of stem cells to the damaged tissue.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070238680 - Substance and process for preventing a genetic defect from being passed onto offspring: A substance and process for preventing reproductive cells containing a genetic defect from being passed onto offspring by creating conditions, such as by adding a particular substance to extra-cellular fluid, that triggers or activates the particular disease associated with the genetic defect in defective reproductive cells, rendering those cells incapable... Agent: Jeffrey M Hersh Attorney At Law

20070238694 - Purine compounds and methods of use thereof: The invention relates to Purine Compounds; compositions comprising an effective amount of a Purine Compound; and methods for reducing a subject's rate of metabolism or protecting a subject's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070238696 - Dosage unit for cardioprotection: A method for secondary cardiovascular prevention in a patient includes formulating a single dosage unit containing a beta-adrenergic blocking agent and a cholesterol-lowering agent that is a statin where the single dosage unit contains a quantity of medications sufficient for secondary prevention of a heart attack in the patient, and... Agent: Mesmer & Deleault, PLLC

20070238697 - Pharmaceutical compositions and methods relating to fucans: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.... Agent: Graybeal, Jackson, Haley LLP

20070238698 - Method for manufacturing drinking water having chitosan: A method to make chitin dissolve into and stored in the acid water to obtain drinking water having chitosan includes putting water into chitin. By mixing or an adequate vibration, the drinking water having granular chitosan is produced. Further, the granular chitosan in the water has excellent preservative and stable... Agent: Hdsl

20070238699 - Compounds for the treatment of proliferative disorders: m

20070238701 - 2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof: Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070238704 - 2-substituted-1alpha,25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof: Compounds of formula I, II or III are provided where X1, X2 and X3 are independently selected from H and hydroxy protecting groups and R1 and R2 are independently selected from H or straight or branched chain alkyl groups having from 1 to 8 carbon atoms, straight or branched chain... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238700 - N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites: Novel N-phenyl-1,1,1-trifluoromethanesulfonamide compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo and ex vivo.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070238708 - Acute inflammatory condition treatment: This invention provides a method for prophylaxis or treatment of an acute inflammatory disorder, comprising administering to a patient an effective amount of pharmaceutically acceptable bodies carrying an effective number of phosphate-containing groups presented or presentable on the surface of said bodies, the phosphate-containing groups comprising a plurality of phosphate-glycerol... Agent: Foley & Lardner LLP

20070238709 - Mitoquinone derivatives used as mitochondrially targeted antioxidants: This invention relates to methods to screen for, identify, select and synthesise amphiphilic mitochondrially targeted antioxidant compounds, and compositions, dosage forms and methods reliant on said compounds. The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms and... Agent: Seed Intellectual Property Law Group PLLC

20070238710 - N-aryl-n'alkyl sulfamides as mek inhibitors: This invention concerns N-(ortho phenylaminoaryl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070238711 - Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of minocycline, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple... Agent: Cooper & Dunham, LLP

20070238712 - 19-nor-vitamin d analogs with 1,2 or 3,2 heterocyclic ring: 19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity in mobilization of bone, making them therapeutic agents for the treatment or prophylaxis of osteoporosis,... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20070238713 - Methods for prevention and treatment of conditions arising from local estrogen deficiency: The present invention relates to methods for the prevention and treatment of conditions arising from local estrogen deficiency, such as dyspareunia, vulvar atrophy, vaginal atrophy, vaginal dryness, vulvar itching, vaginal itching, vulvar burning, vaginal burning, vulvar dystrophy, atrophic vaginitis or menopausal sexual dysfunction. In some embodiments, the methods include systemic,... Agent: Pepper Hamilton LLP/wyeth

20070238714 - Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases: The present invention relates to methods and uses for preventing or treating hormone-dependent diseases, in particular breast cancer, in a mammal, by a combination of an antiprogestin, in particular the antiprogestin 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, and a pure antiestrogen, in particular a compound of general... Agent: Millen, White, Zelano & Branigan, P.C.

20070238715 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070238716 - Statin stabilizing dosage formulations: The present invention relates to pharmaceutical formulations containing 7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid, or pharmaceutically acceptable salts thereof, and a stabilizing agent.... Agent: Sheridan Ross PC

20070238717 - Neuroprotection with beta-lactam compounds: Described herein are methods of treating or preventing neurological disease and disease symptoms using beta-lactam compounds, and compounds useful for treating disease and disease symptoms.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070238718 - Thiazolyl-dihydro-indazole: wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070238720 - Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070238719 - Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures: The present invention relates to methods for reducing the risk of infection due to surgical or invasive medical procedures. The present invention also relates to methods for preventing infection due to surgical or invasive medical procedures.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070238721 - Highly selective novel amidation method: The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group, which comprises reacting functional group-selectively using an inexpensive condensing agent without protecting the carboxyl group by esterification, that is, reacting carboxylic acid anhydride obtained by reacting... Agent: Edwards Angell Palmer & Dodge LLP

20070238722 - N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones: e

20070238723 - Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20070238724 - Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070238725 - Therapeutic combinations for the treatment or prevention of psychotic disorders: e

20070238726 - Heterobicyclic pyrazole compounds and methods of use: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts... Agent: Viksnins Harris & Padys Pllp

20070238727 - 5-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones and analogs as anti-virals: Compounds of formula (I) the N-oxides, salts, stereoisomeric forms, prodrugs, esters and metabolites thereof, wherein X is NR2, O, S, SO, SO2; R1 is hydrogen, cyano, halo, a carbonyl derivative, methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)-methanimidamidyl, Het1 or Het2; n is 1, 2 or 3; R2 is (i) aryl substituted with... Agent: Philip S. Johnson Johnson & Johnson

20070238728 - Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them: m

20070238729 - Dna-pk inhibitors: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or... Agent: Michael Best & Friedrich LLP

20070238730 - Thiazolyl-dihydro-cyclopentapyrazole: wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070238731 - Dna-pk inhibitors: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached,... Agent: Michael Best & Friedrich LLP

20070238732 - Brimonidine and timolol compositions: Disclosed herein are compositions comprising brimonidine and timolol. Methods and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20070238733 - Compositions useful as inhibitors of voltage-gated sodium channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070238734 - Jnk inhibitors: e

20070238735 - Cyclooxygenase-2 selective inhibitors, compositions and methods of use: The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions and kits comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or... Agent: Wilmerhale/nitromed

20070238736 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: e

20070238737 - Novel compounds:

20070238738 - Crystalline ziprasidone hci and processes for preparation thereof: Provided is crystalline ziprasidone HCl and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20070238739 - Process for purifying n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process: Provided are novel Zaleplon crystalline Forms II, III, IV and V, which are useful for the treatment of insomnia.... Agent: Kenyon & Kenyon LLP

20070238740 - Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use: The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at... Agent: Wilmerhale/nitromed

20070238742 - Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d]pyrimidine and their biological activities and related compositions and methods of treatment: Stereoselective methods for preparing the individual isomers, E- and Z-2,4-substituted-5-vinylfuro[2,3-d]pyrimidine and pharmaceutically acceptable salts, solvates, and prodrugs thereof using selective synthetic conditions are provided. This class of pyrimidine compounds function as receptor tyrosine kinase inhibitors during angiogenesis and resists the development of new blood vessels in tumors as well as... Agent: Eckert Seamans Cherin & Mellott

20070238741 - Rho-kinase inhibitors: Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.... Agent: Millen, White, Zelano & Branigan, P.C.

20070238743 - 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases: Novel substituted pyrimido[4,5-d]pyrimidin-2-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070238744 - Use of 6-(2-tolyl)-triazolopyrimidines as fungicides, novel 6-(2-tolyl)-triazolopyrimidines, method for the production thereof, used there of for controlling harmful fungi, and agents containing the same: v

20070238745 - Pi3k-akt pathway inhibitors: A treatment for cancer using a combination therapy including an inhibitor of the PI3K/Akt pathway in combination with roscovitine. It is shown that the combination of roscovitine and API-2 (Triciribine) or roscovitine and LY294002 induce the apoptosis of androgen-dependent (LNCaP) and androgen-independent (PC3) prostate cancer cells. Two important results have... Agent: Smith Hopen, Pa

20070238746 - Thiazolyl-dihydro-chinazoline: wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070238747 - Rifamycin analogs and uses thereof: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin,... Agent: Clark & Elbing LLP

20070238749 - Alpha2delta ligands for the treatment of fibromyalgia and other disorders: e

20070238748 - Methods for treating diseases with 4-hydroxybenzomorphans: 4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070238750 - Pure isomers of tritoqualine: The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.... Agent: Mandel & Adriano

20070238751 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070238752 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Glaxosmithkline Corporate Intellectual Property-uw2220

20070238754 - Novel cb 1 receptor inverse agonists: s

20070238753 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv): The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.... Agent: Robert Deberardine Abbott Laboratories

20070238755 - Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue: The present invention relates to methods useful for treating and/or preventing radiation- and/or chemical-induced toxicity in non-malignant tissue using a protease activated receptor-1 (PAR-1) inhibitor. In particular, use of a protease activated receptor-1 (PAR-1) inhibitor to treat and/or prevent acute and chronic adverse effects of radiation and/or chemical exposure (e.g.,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070238758 - Agent for inhibition of cytokine production and agent for inhibition of cell adhesion: e

20070238756 - Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus: A method for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a dipeptidyl peptidase IV inhibitor and another antidiabetic agent, to a mammal in... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070238757 - Novel treatment: A method for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, injury or impaired plasticity which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a PPARγ agonist or a pharmaceutically acceptable derivative thereof.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070238759 - Novel polymorph v of torasemide: The invention relates to a novel polymorph V of torasemide, to a process for its preparation, to its use as a raw material for the preparation of crystalline modifications I and III of torasemide, to amorphous torasemide modifications and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the... Agent: Connolly Bove Lodge & Hutz LLP

20070238760 - Diagnosis and treatment of human kidney diseases: Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to... Agent: Covington & Burling, LLP Attn: Patent Docketing

20070238761 - Use of pyridoxamine to treat and/or prevent disease processes: Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070238763 - Urea derivatives as integrin a4 antagonists: Novel antagonists of α4β1 integrin and/or α4β7 integrin are described in this application.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070238762 - Use of antagonists of hepatic sympathetic nerve activity: The present invention provides pharmaceutical compositions comprising antagonists of hepatic sympathetic activity and methods for using said pharmaceutical compositions for treatment of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic... Agent: Merchant & Gould PC

20070238764 - Use of sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of depigmentation agent: The invention relates to using a composition comprising an association of at least one type of nicotinic acid or nicotinic acid amide and at least one type of sphingoid base in the form of a depigmentation agent. The use of the inventive composition makes it possible simultaneously to promote skin... Agent: Buchanan, Ingersoll & Rooney PC

20070238765 - Heterocyclic gabaa subtype selective receptor modulators: e

20070238766 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070238767 - Thiazoline acid derivatives: The present invention relates to novel thiazoline acids and derivatives thereof useful as chelators of trivalent metals in therapeutic applications. For example, the thiazoline acid derivatives are useful in diagnosing and treating pathological conditions associated with an excess of trivalent metals in humans and animals.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070238768 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070238769 - Bone densifying agent characterized by use of cathepsin k inhibitor with pth: The present invention relates to an agent for increasing BMD characterized by use of a cathepsin K inhibitor as a bone resorption inhibitor in combination with a type of PTH as a bone formation stimulator. This agent for increasing BMD is useful for the treatment of osteoporosis, bone fracture, arthritis,... Agent: Sughrue-265550

20070238770 - Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations: e

20070238771 - Indoles and benzoimidazoles as histamine h4 receptor modulators: Benzoimidazole and indole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20070238772 - Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder: The invention relates more particularly to the use of metronidazole for the preparation of a pharmaceutical composition for treating a cutaneous vascularization disorder.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070238773 - Compositions and methods of treatment using modulators of motoneuron diseases: The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); a method for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in... Agent: Morgan, Lewis & Bockius, LLP

20070238774 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat... Agent: Glaxosmithline Corporate Intellectual Property - Uw2220

20070238775 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20070238776 - Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine: The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs,... Agent: Kelley Drye & Warren LLP

20070238777 - Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight: The invention relates to the use of one or several synthetic or natural furan alkyls for preparing a drug preventing and/or treating obesity or overweight. The use of one or several synthetic or natural furan alkyls for cosmetically treating local excessive weight is also disclosed. Said furan alkyls preferably correspond... Agent: Foley And Lardner LLP Suite 500

20070238778 - Method for producing enantiomeric form of 2,3-diaminopropionic acid derivatives: The invention relates to a method for producing enantiomeris form of 2,3-diaminopropionic acid derivatives of formula (I) by asymetric hydrogenation from compounds of formula (II).... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070238779 - Carisoprodol articles and methods: A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the Cmax for carisoprodol compared to administration in the absence of food. In one embodiment, informing comprises providing printed labeling instructions. Also included are articles comprising a carisoprodol formulation and prescribing... Agent: Cantor Colburn, LLP

20070238781 - Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex: The invention relates to compounds for the modulation of the glycolysis enzyme complex and of the transaminase complex, pharmaceutical compositions containing such compounds as well as uses of such compounds for preparing pharmaceutical compositions for treating various diseases.... Agent: Mayer Fortkort & Williams, PC

20070238780 - Multifunctional enhancement systems for personal care, household, and wood products: A personal care product, a household product, an industrial formulation, or a medicinal product of at least a fluorosurfactant and/or a natural or naturally-derived or synthetic, and/or *Eco-friendly (See Description) materials such as PEG-4 rapeseedamide, glycerth 2-cocate, Behenamidopropyl dimethylamine, and lactic acid (and derivatives of) as components and at least... Agent: Irving M. Fishman

20070238782 - Naphthalenedione compounds: p

20070238783 - Beta-benzyloxyaspartate derivatives with amino group on benzene ring: wherein R is hydrogen, a linear or branched lower aliphatic acyl group with the acyl portion optionally substituted, an alicyclic acyl group, an aromatic acyl group with a substituent on the aromatic ring, an amino acid-derived group or a biotin derivative-derived group, having an amino substituent on the benzene ring,... Agent: Manelli Denison & Selter

20070238784 - Anthracenedione compounds: e

20070238785 - Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders: The present invention relates to the use of a specific antagonist of TP receptors in obtaining medicaments intended for the treatment of vascular disorders in patients having had a previous cerebral vascular accident, especially for reducing cerebrovascular and cardiovascular events in patients having had a previous cerebral ischaemic accident (CIA)... Agent: The Firm Of Hueschen And Sage

20070238786 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070238787 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 μg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070238788 - Treatment of renal disorders, diabetic nephropathy and dyslipidemias: Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to... Agent: Millen, White, Zelano & Branigan, P.C.

20070238789 - Prednisolone acetate compositions: Prednisolone acetate compositions, and methods, eye drops, and medicaments related thereto, are disclosed herein.... Agent: Allergan, Inc.

20070238790 - Methods and compositions for making and using polymorphs of cinacalcet: The present invention is directed to methods and compositions for making and using a new polymorph of cinacalcet hydrochloride.... Agent: Marshall, Gerstein & Borun LLP

20070238791 - Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using rxr modulators: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds that are modulators of Retinoid X Receptors are provided.... Agent: Fish & Richardson, PC

20070238792 - Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using rxr modulators: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.... Agent: The Firm Of Hueschen And Sage

20070238793 - Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status: Methods for the reduction or prevention of oxidative stress in a human subject comprising administering to the human subject an effective amount of a composition comprising xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene are described. Also described are compositions comprising xanthophyll carotenoids, or... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20070232539 - Lipid therapy: A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand... Agent: Blakely Sokoloff Taylor & Zafman

20070232546 - Linear natriuretic peptide constructs: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group covalently bound to a reactive group of at least one of the amino acid residues or surrogates, pharmaceutical compositions including such linear constructs, and methods of... Agent: Palatin Technologies, Inc.

20070232561 - Pharmaceutical compositions for promoting wound healing: The present invention relates to pharmaceutical compositions and methods for promoting wound healing. The invention also relates to methods of making pharmaceutical compositions disclosed herein. Pharmaceutical compositions are disclosed comprising an effective amount of a 2-alkoxyadenosine or 2-aralkoxyadenosine, about 10% to about 70% w/w propylene glycol and a thickening agent.... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20070232562 - Antiviral nucleosides: Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070232566 - Formulations of low dose diclofenac and beta-cyclodextrin: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in... Agent: Baker Botts L.L.P.

20070232567 - Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin: The present invention is directed to pharmaceutical compositions containing (a) a dosage of a non-steroidal anti-inflammatory drug (NSAID) effective to induce analgesia an anti-inflammatory effect, or an anti-pyretic effect and (b) a beta-cyclodextrin compound; wherein the dosage of the NSAID compound is less than the minimum approved dose for the... Agent: Baker Botts L.L.P.

20070232569 - Treatments for cancer: Phenyl boric acid and its salts and substituent derivatives (e.g., substituted phenyl) effectively inhibit the growth of several cancer cell lines and offers utility in the treatment/prevention of cancer. The material may be applied or injected into affected areas or applied topically, especially for the treatment of cervical cancer.... Agent: Mark A. Litman & Associates, P.A. York Business Center

20070232522 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.... Agent: EagleIPLimited

20070232521 - Fluoride carrier for positron emission tomography: wherein R1 is an ammonium bridge. The compounds of the present invention can be linked to a biological molecule that targets a specific type of cell. The compounds of the present invention can trap isotopic fluorine so that when the biological molecule accumulates in the desired type of cell, the... Agent: Townsend And Townsend And Crew, LLP

20070232519 - Human g protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In some embodiments, the GPCR is mammalian, preferably human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gq. In... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20070232523 - Methods and compositions for treating ocular disorders: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in... Agent: David S. Resnick Nixon Peabody LLP

20070232520 - Modulator of tnf/ngf superfamily receptors and soluble oligomeric tnf/ngf superfamily receptors: The present invention generally concerns novel proteins which bind to the intracellular domains of the p55 and p75 TNF-Rs and the FAS-R, which are capable of modulating the function of the p55 and p75 TNF-Rs and the FAS-R, and the DNA sequences which encode them. The present invention also concerns... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070232524 - Oral administration of calcitonin: Disclosed is a particular method of orally administering pharmaceutical compositions comprising calcitonin in combination with oral delivery agents, prior to the consumption of food in humans, and a method of treatment of disorders responsive to the action of calcitonin employing such method of administration; also oral calcitonin pharmaceutical compositions with... Agent: Novartis Corporate Intellectual Property

20070232525 - Method of treating pancreatitis: The present invention provides a method of treating pancreatitis comprising administering to a human in need thereof an effective amount of hemin. The administration of hemin is preferably parenteral. In another aspect, the present invention provides a method of pancreatitis prophylaxis comprising administering to a human in need thereof an... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070232526 - Bovine osteopontin formulations for the improvement of the wound healing process: Topical formulations containing bovine osteopontin for improved wound healing. The wound can be infected or inflamed or it can be a diabetic wound.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070232528 - Formulation comprising histone deacetylase inhibitors: The present invention relates to an orally available galenics formulation of Valproic Acid or derivatives thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation... Agent: Smith Patent Consulting Consulting, LLC

20070232527 - Medicaments and methods combining a hcv protease inhibitor and an akr competitor: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of a hepatitis C virus (HCV) protease inhibitor and an aldo-keto reductase (AKR) competitor, for concurrent or consecutive administration in treating, preventing, or ameliorating one or more symptoms of HCV, treating disorders associated with HCV, or inhibiting cathepsin... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070232529 - Active agent delivery systems and methods for protecting and administering active agents: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.... Agent: Hunton & Williams LLP Intellectual Property Department

20070232532 - Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders: e

20070232530 - Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders:

20070232531 - Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders:

20070232534 - Compound for promoting the growth of neural cells: The compound of the present invention can increase the survival rate of neural cells even at a low cellular density in a culture medium. The compound of the present invention can also promote the growth of neurons, which is revealed by the increase in the thickness, length and number of... Agent: Morris Manning Martin LLP

20070232535 - Gfralpha3 and its uses: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFRα3, a novel α-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an α-subunit... Agent: Heller Ehrman LLP

20070232537 - Intranasal pyy formulations with improved transmucosal pharmacokinetics: What is described is an aqueous Y2 receptor-binding peptide formulation for enhanced intranasal delivery of a Y2 receptor-binding peptide, comprising said Y2 receptor-binding peptide, a buffer salt, and having a pH between about 3.0 and about 6.0, wherein said buffer salt comprises a net single ionogenic moiety with a pKa... Agent: Nastech Pharmaceutical Company Inc

20070232542 - Methods for modifying cell motility using factor viia antagonist: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK... Agent: Novo Nordisk, Inc. Patent Department

20070232541 - Methods of regulating angiogenisis through stabilization of pedf: The invention provides methods of inhibiting angiogenesis within a tissue, promoting neuron protection within a tissue, and treating a disease in a mammal, wherein (a) a gene transfer vector encoding a protein of a serpin superfamily or a therapeutic fragment or variant thereof or (b) a protein of a serpin... Agent: Leydig Voit & Mayer, Ltd

20070232536 - Pharmaceutical compositions containing plasma protein: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070232543 - Ribonucleases and methods of making them recombinantly: Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.... Agent: Mark H. Jay, P.A.

20070232544 - Ribonucleases and methods of making them recombinantly: Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.... Agent: Mark H. Jay, P.A.

20070232540 - Treatment of ischemia: A system, including methods and compositions, for treatment of ischemia.... Agent: Black Lowe & Grham PLLC

20070232533 - Use of vinca alkaloids and salts thereof: An agent containing a vinca alkaloid or its pharmacologically acceptable salt as an active ingredient can induce insulin production and/or secretion of non-neoplastic cells derived from the pancreas.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070232538 - Uses of polypeptides: The present invention provides uses of a polypeptide having a ligand activity to a sensory epithelium neuropeptide-like receptor (SENR) which is a G protein-coupled receptor protein, and a DNA encoding the same. More specifically, the present invention provides an anti-attention-deficit-disorder or anti-narcolepsy agent, which comprises a polypeptide having a ligand... Agent: Edwards Angell Palmer & Dodge LLP

20070232545 - Compositions and methods for treating atherosclerosis: Reverse peptides and mimetics of a mammalian serum amyloid A isoform 2.1 (SAA2.1) domain or a portion thereof and compositions and pharmaceutical compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity. Methods of using these reverse peptides, mimetics thereof and compositions in the treatment and/or... Agent: Licata & Tyrrell P.C.

20070232547 - Two synthetic peptides for treatment and prevention of cancers: Two synthetic peptides, Atroporin (AT) and Kaotree (KT), each consisting of ten amino acids and their use for the treatment and/or prevention of various types of cancers is disclosed. The amino acid sequence from the N-terminal for AT is Phe-Cys-Arg-Phe-Leu-Leu-Cys-Pro-Ser-Arg, and for KT is Pro-Pro-Gly-Asn-Gln-Pro-Asp-Ala-Asp-Ser.... Agent: John R. Casperson

20070232548 - Enhancement of endogenous gonadotropin production: Provided herein is a method of enhancing endogenous gonadotropin and androgen production comprising administering a therapeutically effective amount of at least one GnRH agonist to a patient in need of such treatment.... Agent: Steven F. Weinstock Abbott Laboratories

20070232549 - Novel peptides as ns3-serine protease inhibitors of hepatitis c virus: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070232551 - Treatment for cardiovascular disease: This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering... Agent: Beusse Wolter Sanks Mora & Maire

20070232550 - Use of hamlet (human alpha-lactalbumin made lethal to tumour cells) for treating viral infections: The use of a biologically active complex of α-lactalbumin, selected from HAMLET (human α-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of viral infections.... Agent: Nixon & Vanderhye, PC

20070232552 - Oxophytodienoic acid conjugates as ecological pesticides: Novel 12-oxophytodienoic acid (OPDA) conjugates named Arabidopside E and G, for improving plant resistance to pathogen attack and/or spread of a pathogen. This is of particular interest in attempts to develop an efficient plant-pesticide and improve the performance of pesticides with regard to efficiency and minimizing negative environmental effects. The... Agent: Lynn E Barber

20070232553 - Modulation of innate immunity receptors' signaling by micrornas mir-146a and mir-146b: The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor... Agent: Knobbe Martens Olson & Bear LLP

20070232554 - 3,6-bridged 9,12-oxolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070232555 - C-met sirna adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity: Suppression of the Hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth. Using RNA interference (RNAi) technology and adenoviruses carrying siRNA (Ad Met siRNA) target sequences dramatically reduced Met expression in mouse, dog and human tumor cells.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070232557 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous... Agent: Wyeth Patent Law Group

20070232556 - Methods and compositions for the treatment of neurological diseases and disorders: Methods and compositions are provided for preventing or treating neurodegenerative disease and other related diseases and disorders in a mammalian subject. The method provides administering to the mammalian subject a compound capable of inhibiting a PGE2 receptor, e.g., subtype EP2, wherein the compound is administered in an amount effective to... Agent: Woodcock Washburn LLP

20070232558 - Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen: A DNA vaccine for the treatment of prostate cancer, comprising a plasmid vector comprising a nucleotide sequence encoding SSX-2 operably linked to a transcription regulatory element, wherein upon administration to a mammal a cytotoxic immune reaction against cells expressing SSX-2 is induced. In one embodiment, the SSX-2 encoded is a... Agent: Quarles & Brady LLP

20070232559 - 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof: D

20070232560 - Treatment of skin with adenosine or adenosine analog: Methods for enhancing the condition of non-diseased skin by application of compositions containing adenosine or an adenosine analog are disclosed. Also disclosed are methods for increasing DNA synthesis or protein synthesis in dermal cells, and methods for increasing dermal cell size, by application of compositions containing adenosine.... Agent: Fish & Richardson PC

20070232563 - Method for enhancing biological activity and/or expanding suitable region for biological activity of living body contacting with aqueous environment: The present invention has an object to provide a method for enhancing biological activity and/or expanding suitable region for biological activity of living bodies contacting with aqueous environment, and solves the above object by providing a method for enhancing biological activity and/or expanding suitable region for biological activity of living... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070232564 - Fish-origin chondroitin sulfate/dermatan sulfate hybrid chain: It is intended to provide a novel chondroitin sulfate/dermatan sulfate hybrid chain having biding activity toward a variety of growth factors, neurite outgrowth-promoting activity, and anticoagulant activity and to provide a composition for neurological disease treatment. The novel chondroitin sulfate/dermatan sulfate hybrid chain was separated and purified from the bodies... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070232565 - Novel polysaccharides and oligosaccharides: Polysaccharides and oligosaccharides having activity of binding to different proliferation factors and neurite outgrowth-promoting activity and compositions for neurological disease treatment, compositions for inflammatory disease treatment, or compositions for wound treatment, which comprise such polysaccharides and oligosaccharides, are provided. Chondroitin sulfate/dermatan sulfate hybrid chains, chondroitin sulfate C, and oligosaccharides derived... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070232568 - Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome: One aspect of the present invention is concerned with a method of treating or preventing pulmonary inflammation as a complication ensuing from physical trauma, bacteraemia or viral inflection, said method comprising enterally administering at least one or more glutathione promoters selected from: −0.3-20 g, preferably 0.5-5 g pyruvate equivalents; −0.1-5... Agent: The Webb Law Firm, P.C.

20070232570 - 11-phosphorous steroid derivatives useful as progesterone receptor modulators: The present invention is directed to novel 11-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070232571 - Novel heteroaromatic inhibitors of fructose-1,6-bisphosphatase: e

20070232572 - Chemical derivatives as antitelomerase agents which bind specifically to the g-quadruplex dna structures and their application as a specific anticancer agent: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds and their therapeutic application in humans.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070232573 - Ethanoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel Ethanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070232574 - 2-oxothiazolidine 4-carboxylic acid compounds for promoting desquamation of the skin: e

20070232576 - Sulfated molecular umbrellas as anti-hiv and anti-hsv agents: in which CPS (the structure within the square brackets) is a cholanic acid derivative. R1 to R16 are chosen independently from H, OH and OSO3−A+. W is a direct bond or a deshydrogen residue of a C3-C6 diol or triol. A is chosen from H+, a quaternary ammonium species and... Agent: Heslin Rothenberg Farley & Mesiti PC

20070232577 - Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin: The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070232575 - Treatment of pulmonary artery hypertension with dhea, dheas, dhea analogs, or dhea derivatives: The present invention is related to the treatment and prevention of pulmonary vascular diseases. Administration of dehydroepiandrosterone (DHEA) has been found to prevent and decrease pulmonary artery hypertension. Accordingly, the invention discloses methods of treating or preventing pulmonary vascular diseases such as pulmonary artery hypertension by pulmonary administration of compositions... Agent: Knobbe Martens Olson & Bear LLP

20070232578 - Crystalline forms of ciclesonide: The invention encompasses a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 11.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta±0.2 degrees two-theta, methods of its preparation and pharmaceutical compositions thereof.... Agent: Kenyon & Kenyon LLP

20070232579 - Nitrated lipids and methods of making and using thereof: Described herein are nitrated lipids and methods of making and using the nitrated lipids.... Agent: Fish & Richardson P.C.

20070232580 - Novel sterol/stanol nitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders: Sterol and stanol nitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed nitro derivatives are synthesized by ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound.... Agent: Kirton And Mcconkie

20070232581 - Oxime-containing acyl guanidines as beta-secretase inhibitors: or a stereoisomer; or a nontoxic pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070232582 - 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors: The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which have β-lactamase inhibitory and antibacterial properties. The compounds are therefore useful in the treatment of antibacterial infections in humans or... Agent: Wyeth Patent Law Group

20070232583 - Pyridine and pyrimidine derivatives as mgiur2 antagonists: e

20070232584 - Composition and method for the treatment of tauopathies: The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as... Agent: Lahive & Cockfield, LLP

20070232585 - Sigma receptor inhibitors: The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula (I) and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and prophylaxis, in particular for the treatment of psychosis or pain.... Agent: Morgan & Finnegan, L.L.P.

20070232586 - Hydrazino-substituted heterocyclic nitrile compounds and use thereof: (wherein ring X is a heterocyclic group which may contain 1 to 4 hetero atoms selected from an nitrogen atom(s), a oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to said nitrogen atom in the ring; J is a bond or a spacer having from 1... Agent: Sughrue-265550

20070232587 - Homotropanes with central nervous system activity: Disclosed are novel homotropane compounds with CNS activity. These compounds can be used for alleviating symptoms of CNS disorders.... Agent: Hodgson Russ LLP The Guaranty Building

20070232588 - Anti-parasitic and/or anti-viral and/or anti-microbial compositions: Voacamine and its natural and synthetic derivatives such as 16′-decarbometheoxyvoacamine, N6-demethylvoacamine, voacamidine, tabernamine, ervahamine A, vobasine and coronaridine are useful as anti-microbial, anti-parasitic and anti-viral agents. A basic extract of the tertiary alkaloids present in plants of the genus Peschiera or Voacanga, especially Peschiera fuchsiaefolia can be isolated and used... Agent: George A. Seaby Seaby & Associates

20070232589 - Pharmaceutical composition and method for treating neurodegenerative disorders: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition an acetylcholine esterase inhibitor in combination with another therapeutic agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070232590 - 3-cylcoalkylbenzazepines as histamine h3 antagonists: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070232591 - Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals... Agent: Edward Angell Palmer & Dodge, LLP Neurogen Corporation

20070232593 - Antifungal 4-substituted 5,6-dihydro-4h-pyrrolo [1,2-a][1,4]benzodiazepines: e

20070232592 - Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine: The invention concerns the use of a therapeutic composition comprising at least one pyrrolobenzodiazepine derivative combined with fludarabine for treating cancer and more particularly hematological diseases.... Agent: Hunton & Williams LLP Intellectual Property Department

20070232594 - Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both: e

20070232595 - Method for accelerating cutaneous barrier recovery: A method for accelerating cutaneous barrier recovery and a method for preventing epidermal hyperplasia by inhibiting production of Nitric Oxide by an epidermal cell are provided.... Agent: Snider & Associates

20070232596 - Benzothienopyridines for use as inhibitors of eg5 kinesin: m

20070232598 - Combination of active substances with insecticidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, compounds which act as insecticides on nicotinergic acetylcholine receptors as agonists and antagonists, and at least one active compound from the group of the anthranilamides, which combinations are suitable for protecting plants against attack by pests.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070232597 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070232600 - Anti-migraine treatments: The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of... Agent: Louis J. Wille Bristol-myers Squibb Company

20070232599 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070232601 - Vla-4 inhibitor: s

20070232602 - Thiophene derivatives, their manufacture and use as pharmaceutical agents: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070232604 - Imidazolothiazole compounds for the treatment of disease: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.... Agent: Jones Day

20070232605 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general formula I as well as the production and use thereof as a medication.... Agent: Millen, White, Zelano & Branigan, P.C.

20070232603 - Small-molecule modulators of trp-p8 activity: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating... Agent: Townsend And Townsend And Crew, LLP

20070232606 - Compounds and compositions as cathepsin s inhibitors: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.... Agent: Novartis Corporate Intellectual Property

20070232607 - Quinazoline derivatives as erbb receptor tyrosine kinases: The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament... Agent: Morgan Lewis & Bockius LLP

20070232608 - Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them: e

20070232609 - Novel antiparasitic combination of active compounds: The present invention relates to the combined use of substituted benzimidazoles and 1,2,4-triazine compounds against parasitic protozoa, in particular coccidia.... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20070232610 - Novel compounds that are erk inhibitors: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070232611 - Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents: The present invention relates to novel amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I).... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070232612 - Octahydro-pyrrolo[3,4-b]pyrrole derivatives: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.... Agent: Robert Deberardine Abbott Laboratories

20070232613 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: t

20070232614 - Therapeutic agent for nonviral hepatitis:

20070232615 - Chemical compounds: The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070232616 - Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor: Benzoimidazol-2-yl pyridines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20070232617 - Indole-type derivatives as inhibitors of p38 kinase: The invention is directed to methods to inhibit p38-α kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.... Agent: Morrison & Foerster LLP

20070232618 - Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070232619 - Piperazine derivatives of dialkyl oxindoles: The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein R1 stands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; R2 represents hydrogen or halogen; R3 denotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying... Agent: Birch Stewart Kolasch & Birch

20070232620 - 3-aminoindazoles: Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type.... Agent: Millen, White, Zelano & Branigan, P.C.

20070232621 - Linear dicationic terphenyls and their aza analogues as antiparasitic agents: Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070232622 - Small molecule toll-like receptor (tlr) antagonists: The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically... Agent: Wolf Greenfield & Sacks, P.C.

20070232623 - Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them: e

20070232625 - Fungicidal mixtures:

20070232624 - Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients: The present invention provides a pharmaceutical composition, and provides for the use thereof for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof. The pharmaceutical composition comprises a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms, and... Agent: Philip S. Johnson Johnson & Johnson

20070232626 - Purine derivatives as a3 and a1 adenosine receptor agonists: Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases,... Agent: Leydig, Voit & Mayer, Ltd.

20070232627 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using... Agent: Robert Deberardine D-377/ap6a-1

20070232628 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070232629 - Adhesive patch: The object of the invention is to provide a patch that contains tandospirone or a pharmaceutically acceptable salt thereof as the drug component, and has a sufficiently high percutaneous absorption rate. A patch according to a preferred embodiment of the invention comprises a backing layer and a pressure-sensitive adhesive layer... Agent: Nath & Associates

20070232630 - Macrocycle derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to macrocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.... Agent: Philip S. Johnson Johnson & Johnson

20070232631 - Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (bpu) sulfur analogs: A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6n was more effective than compound 1 in causing apoptosis of... Agent: Pearl Cohen Zedek Latzer, LLP

20070232633 - Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase: The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the... Agent: Merchant & Gould PC

20070232632 - Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs: e

20070232635 - Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists: represents an optional double bond and wherein Gn, Jn, R3, R8, R9, R10, R11, R32, R33, B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070232634 - Tetrahydropyridines with central nervous system activity: Provided are novel tetrahydropyridine derivatives bearing substituents. These compounds can be used for alleviating the symptoms of CNS disorders.... Agent: Hodgson Russ LLP The Guaranty Building

20070232636 - Substituted diaza-spiro-[5.5]-undecane derivaties and their use as neurokinin antagonists: o

20070232637 - Combinations comprising antimuscarinic agents and pde4 inhibitors: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent: Hoxie & Associates LLC

20070232638 - Opiopathies: The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture... Agent: David A. Lowin

20070232639 - Camptothecin derivatives conjugated in position 20 with integrin antagonists: Compounds or formula (I) are described, in which the R and R1 groups are as defined here below and include the condensation of the camptothecin molecule in position 20 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5... Agent: Nixon & Vanderhye, PC

20070232640 - Antifungal and antiparasitic indoloquinoline derivates: with the proviso that, where Z is NH, N—CH3, S or O and Rn is H, R5 may not be CH3; as well as quaternary ammonium salts thereof and their use as pharmacological compositions and for methods of treatment.... Agent: Miles & Stockbridge PC

20070232642 - 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to 2-amino-3,4-dihydro-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.... Agent: Philip S. Johnson Johnson & Johnson

20070232643 - Antitumor agents: wherein Y is F, Cl, Br, methyl or methoxy; and pharmaceutically acceptable salt thereof. The compounds are effective antitumor agent. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070232641 - Novel 9-aza-bicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 9-aza-bicyclo[3.3.1]nonane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070232645 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using... Agent: Robert Deberardine Abbott Laboratories

20070232644 - Inhibitors of the hiv integrase enzyme: m

20070232646 - Tropane prodrugs with central nervous system activity: Disclosed are tropane-based prodrug compounds bearing fatty ester and aromatic substituents. The compounds can be used for alleviating symptoms of CNS disorders.... Agent: Hodgson Russ LLP The Guaranty Building

20070232647 - Use of ppar agonists to treat ruminants: The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver... Agent: Pharmacia & Upjohn

20070232648 - Modulators of the glucocorticoid receptor and method: e

20070232650 - Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid: The present invention is directed to malate salts of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid, and its polymorphs. The present invention is also directed to pharmaceutical compositions comprising the described salts and polymorphs.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070232649 - Heteroaryl sulfones and sulfonamides and therapeutic uses thereof: e

20070232651 - Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof: Disclosed are novel anabaseine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070232653 - Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids: s

20070232652 - Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety: The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070232654 - Novel compounds and compositions as cathepsin inhibitors: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Synnestvedt & Lechner LLP

20070232655 - 2-pyridinylcycloalkylcarboxamide derivatives useful as fungicides: e

20070232656 - Pharmaceutical composition and method for treating neurodegenerative disorders: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase inhibitor and another therapeutic agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070232657 - Novel compounds: The present invention relates to a novel benzamide derivative having pharmacological activity, to processes for its preparation, to compositions containing it and to its use in the treatment of diseases treatable by 5-HT4 receptor activation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070232658 - Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejiction: This invention relates to the use of a compound of formula I, II, III, or IV, as described in the specification, in transplantation and autoimmune diseases.... Agent: Novartis Corporate Intellectual Property

20070232659 - Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070232660 - Therapeutic and delivery methods of prostaglandin ep4 agonists: i

20070232661 - Hedgehog pathway antagonists: Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function.... Agent: Dla Piper US LLP

20070232662 - Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders: The present invention is related to new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prophylaxis of the central nervous system, the gastrointestinal system or the cardiovascular system.... Agent: Birch Stewart Kolasch & Birch

20070232663 - Small molecule insulin mimetics absent quinones: e

20070232664 - Iron binding agents: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070232665 - Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives: The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.... Agent: Myers Bigel Sibley & Sajovec

20070232666 - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20070232667 - Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics: Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, whereby a majority of the nicotinic acid is release and metabolized in the individual within about 5 to about 9 hours. The... Agent: Jonathan N. Provoost, Esq. Kos Pharmaceuticals, Inc.

20070232668 - Orally bioavailable caffeic acid related anticancer drugs: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.... Agent: Fulbright & Jaworski L.L.P.

20070232669 - N-phenylbenzotriazolyl c-kit inhibitors: e

20070232670 - Isothiazole carboxylic acid amides and the application thereof in order to protect plants:

20070232671 - Methods and compositions for treatment of diastolic heart failure: Provided herein are methods of treatment of diastolic heart failure (DHF) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof.... Agent: Jones Day

20070232672 - Pharmaceutical composition and method for treating neurodegenerative disorders: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an acetylcholine esterase inhibitor and another therapeutic agent. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070232673 - 2-imino-benzimidazoles: e

20070232674 - Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases: Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNFα or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.... Agent: Connolly Bove Lodge & Hutz LLP

20070232675 - Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically... Agent: Alcon

20070232676 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent: Merck And Co., Inc

20070232677 - Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds: This disclosure relates to methods of inhibiting vascular hyperplasia using polyamines, polyamine analogs, and conformationally restricted polyamine analogs, or a conjugate of a polyamine, polyamine analog, or conformationally restricted polyamine analog. Polyamines, polyamine analogs, conformationally restricted polyamine analogs, and conjugates thereof are useful in reducing stenosis and restenosis of blood... Agent: Morrison & Foerster LLP

20070232679 - N-aryl pyrrolidine derivatives as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R5′, R6, R7, and p as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070232678 - (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease:

20070232680 - Preparation of ramipril and stable pharmaceutical compositions: A process for preparing ramipril, and stable pharmaceutical compositions containing ramipril.... Agent: Dr. Reddy's Laboratories, Inc.

20070232682 - Indole compounds having sphingosine-1-phosphate (s1p) receptor antagonist: p

20070232681 - Compounds having crth2 antagonist activity:

20070232683 - Crystal form of atorvastatin hemi-calcium and processes for preparation thereof: Provided is a crystal form of atorvastatin hemi-calcium and processes for its preparation.... Agent: Kenyon & Kenyon LLP

20070232684 - Compounds for inhibition of hiv infection by blocking hiv entry: A group of compounds that inhibit HIV replication by blocking HIV entry was identified. Two representative compounds, designated NB-2 and NB-64, inhibited HIV replication (p24 production) with IC50 values <0.5 μg/ml. It was proved that NB-2 and NB-64 are HIV entry inhibitors by targeting the HIV gp41 since: 1) they... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070232685 - Crystalline forms of n-(benzo[b]thien-3-ylmethyl)-sulfamide: The present invention is directed to anhydrous and solvated, crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline forms and their use in the treatment epilepsy and related disorders.... Agent: Philip S. Johnson Johnson & Johnson

20070232686 - Cyanoamidine p2x7 antagonists for the treatment of pain: e

20070232687 - Agent for skin external use containing tocopherol derivative, ascorbic acid derivative and surface active agent having lipopeptide structure: The agent for skin external use of the present invention contains (A) tocopherol glycine esters, (B) ascorbic acid-2-phosphoric acid esters and a specific amount of (C) an anionic surface active agent having a lipopeptide structure. According to the agent for skin external use (including a cosmetic) of the present invention,... Agent: Sughrue Mion, PLLC

20070232688 - Novel sterol/stanol phosphorylnitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders: Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl... Agent: Kirton And Mcconkie

20070232689 - 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers: The present invention is directed to novel 3,4-diamino-3-cyclobutene-1,2-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070232690 - Composition for inducing differentiation of leukemic cells and application thereof: e

20070232691 - Use of ladostigil for the treatment of schizophrenia: Disclosed are methods for the treatment of schizophrenia comprising administering an amount of R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.... Agent: Cooper & Dunham, LLP

20070232693 - Compositions for treating infestation of plants by phytopathogenic microorganisms: The present invention provides compositions and methods for treating the infestation of plants or progeny of plants by phytopathogenic microorganisms. The anti-phytopathogenic microbial compositions are generally effective against of broad spectrum of microbes, such as fungi, yeast and bacteria. Because of their broad spectrum of efficacy, the anti-phytopathogenic microbial compositions... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070232692 - Method of treating cancer using dithiocarbamate derivatives: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions thereof, strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and... Agent: Alston & Bird LLP

20070232694 - Skin cleanser: This invention provides a skin cleanser that comprises an anionic surfactant and a hypochlorite salt, and optionally with an anionic dye and/or an abrasive.... Agent: Knobbe Martens Olson & Bear LLP

20070232695 - Gelled periodontal anesthetic preparation: A composition for anesthetizing oral or buccal tissues, especially periodontal pockets, is provided. The composition has a high concentration of topical anesthetic carried in a non-aqueous liquid vehicle containing a gelling agent. The anesthetics are optionally stabilized in the solution by ion-exchange complexation. The composition can anesthetize the gingivae for... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070232696 - Valproic acid and derivatives thereof as histone deacetylase inhibitors: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of those compounds for the manufacture of a medicament for the treatment of diseases which are associated with hypoacetylation of... Agent: Reed Smith LLP

20070232697 - Method for preparing free base compositions and formulations thereof: Disclosed is a process for preparing a free base composition of a pharmaceutical compound comprising combining an acid addition salt of a pharmaceutical compound, at least one solvent and a sufficient amount of at least one base to convert the acid addition salt of the pharmaceutical to a free base... Agent: Davidson, Davidson & Kappel, LLC

20070232698 - Slimming skin external preparation and cosmetic containing the same: The invention provides a slimming skin external preparation and a cosmetic that contain a carnitine derivative having excellent skin affinity and percutaneous absorption properties and capable of enhancing the fat metabolism, and that can treat, reduce or prevent the obesity by functioning as a lipolytic agent to enhance the fat... Agent: Sughrue Mion, PLLC

20070232699 - Self assembled nanostructures and mehods for preparing the same: The present invention provides amphiphilic diacetylene compounds, and compositions and self-assembled nanotubes containing the same. Also provided are methods of producing the compounds, compositions, and nanotubes of the invention, and methods of destroying or inhibiting the growth or proliferation of microorganisms using the nanotubes of the present invention.... Agent: Calfee Halter & Griswold, LLP

20070232700 - Use of rasagilline for the treatment of restless legs syndrome: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.... Agent: Cooper & Dunham, LLP

20070232701 - Synergistic compositions useful as cytostatic, bacteriostatic and/or virostatic agents: The inventor has surprisingly found that a combination of water-soluble organic compounds provides a synergistic effect that efficiently blocks ATP production by the aerobic pathway. More particularly, such a synergistic composition lowers the level of energy or production of ATP to a point where cells and specifically cancer cells, stop... Agent: Biotech Beach Law Group , PC

20070232702 - Methods and compounds for detection of medical disorders: The invention provides methods for detection of medical disorders, associated with cellular oxidative stress, cell degeneration and/or cell death. The invention further relates to compounds comprising a thiol (—SH) group, for detecting cells undergoing oxidative stress, degeneration and/or a death process. The invention further provides methods for utilizing the compounds... Agent: Pearl Cohen Zedek Latzer, LLP

20070232703 - Composition for preventing and/or treating bone disease, physiologically functional or health food containing thereof, and pharmaceutical containing thereof as active ingredients: e

20070232704 - Heat generating biocompatible ceramic materials for drug delivery: The present invention pertains to injectable heat generating biocompatible ceramic compositions based on hydraulic calcium aluminate, which can be used for therapeutic treatment in vivo, such as tumour treatment, pain control, vascular treatment, drug activation etc, when curing in situ, and which form a biocompatible solid material that can be... Agent: Young & Thompson